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Dementia is a major problem of health in developed societies. Alzheimer’s disease (AD), vascular dementia, and mixed dementia
account for over 90% of the most prevalent forms of dementia. Both genetic and environmental factors are determinant for
the phenotypic expression of dementia. AD is a complex disorder in which many diﬀerent gene clusters may be involved. Most
genes screened to date belong to diﬀerent proteomic and metabolomic pathways potentially aﬀecting AD pathogenesis. The
ε4 variant of the APOE gene seems to be a major risk factor for both degenerative and vascular dementia. Metabolic factors,
cerebrovascular disorders, and epigenetic phenomena also contribute to neurodegeneration. Five categories of genes are mainly
involved in pharmacogenomics: genes associated with disease pathogenesis, genes associated with the mechanism of action of a
particular drug, genes associated with phase I and phase II metabolic reactions, genes associated with transporters, and pleiotropic
genes and/or genes associated with concomitant pathologies. The APOE and CYP2D6 genes have been extensively studied in AD.
The therapeutic response to conventional drugs in patients with AD is genotype speciﬁc, with CYP2D6-PMs, CYP2D6-UMs, and
APOE-4/4 carriers acting as the worst responders. APOE and CYP2D6 may cooperate, as pleiotropic genes, in the metabolism of
drugs and hepatic function. The introduction of pharmacogenetic procedures into AD pharmacological treatment may help to
optimize therapeutics.
1.Introduction
Senile dementia is a major health problem in developed
countries and the primary cause of disability in the elderly.
Alzheimer’s disease (AD) is the most frequent form of
dementia (50–70%), followed by vascular dementia (30–
40%) and mixed dementia (15–20%). These prevalent forms
of age-related neurodegeneration aﬀect over 25 million
people at present, and probably over 75 million people will
be at risk in the next 20–25 years worldwide. The prevalence
of dementia increases exponentially from approximately 1%
at 60–65 years of age to over 30–35% in people older than
80 years. It is very likely that in those patients older than 75–
80 years of age most cases of dementia are mixed in nature
(degenerative + vascular), whereas pure AD cases are very
rare after 80 years of age. The average annual cost per person
with dementia ranges from C10,000 to C40,000, depending
upon disease stage and country, with a lifetime cost per
patient of over C150,000. In some countries, approximately
80% of the global costs of dementia (direct + indirect
costs) are assumed by the patients and/or their families.
About 10–20% of the costs in dementia are attributed to2 International Journal of Alzheimer’s Disease
pharmacological treatment, including antidementia drugs,
psychotropics (antidepressants, neuroleptics, and anxiolyt-
ics), and other drugs currently prescribed in the elderly
(antiparkinsonians, anticonvulsants, vasoactive compounds,
anti-inﬂammatory drugs, etc.). During the past 20 years over
300 drugs have been partially developed for AD, with the
subsequent costs for the pharmaceutical industry, and only 5
drugs with moderate-to-poor eﬃcacy and questionable cost-
eﬀectiveness have been approved in developed countries [1–
3].
Dementia is a multifactorial/complex disorder where
genetic, metabolic, vascular, and epigenetic factors interact
along the lifespan leading to the premature death of neurons.
With the advent of large-scale genomic studies, based on
novel technology used for the mapping of the human
genome, over 1,000 diﬀerent genes have been screened over
the past 20 years, but less than 100 genes have survived rep-
lication studies in diﬀerent populations.
In recent times, signiﬁcant advances have propelled the
introduction of pharmacogenomic approaches in drug
development and also in clinical practice to optimize ther-
apeutics [4–8]. The vast majority of CNS drugs are metab-
olized via enzymes of the cytochrome P450 family (CYPs).
The genes encoding CYP2D6, CYP2C19, CYP2C9,a n dCY-
P3A4/5 isoenzymes are highly polymorphic, with great
allelic variation in diﬀerent ethnic groups. In the Western
population, only 25% of its members are extensive metab-
olizers (EM) for the trigenic cluster integrated by CYPs
2D6 + 2C19 + 2C9, the most relevant genes (and enzyme
products) involved in drug metabolism, together with
CYP3A4/5, which participates in the metabolism of over
80% of common drugs. The other 75% of the population is
potentially at risk for developing adverse drug events (ADRs)
due to defective variants encoding deﬁcient enzymes which
give rise to intermediate (IM), poor (PM), or ultrarapid
metabolizers (UM). This population cluster of defective
metabolizers requires dose adjustment to avoid side eﬀects
[5]. However, not only CYPs are important in terms of drug
eﬃcacy and safety. In fact, 5 categories of genes are mainly
involved in pharmacogenomics: (i) genes associated with
disease pathogenesis (e.g., APP, PSEN1, PSEN2, MAPT,a n d
APOE)[4–6,9,10],(ii)genesassociatedwiththemechanism
of action of a particular drug (e.g., receptor genes) [11,
12], (iii) genes associated with phase I (CYPs) and phase
II reactions (UGTs, SULTs, GSTs,a n dNATs)[ 10, 13–17],
(iv) genes associated with transporters (ABCs,a n dOATs)
[18–22], and (v) pleiotropic genes and/or genes associated
with concomitant pathologies [23]. The APOE and CYP2D6
genes have been extensively studied in AD. Both genes may
inﬂuence pathogenesis and the pharmacogenetic outcome in
patients with dementia.
2. StructuralGenomicsof Alzheimer’s Disease
The genetic defects identiﬁed in AD can be classiﬁed into
three main categories: (a) mendelian mutations in AD
primary genes, (b) multiple susceptibility SNPs in many
diﬀerentgenesdistributedacrossthehumangenome,and(c)
mitochondrial DNA (mtDNA) mutations.
(a) Mendelian or mutational defects in genes are directly
linked to AD, including (i) >30 mutations in the amyloid
beta (Aβ)p r e c u r s o rp r o t e i n( APP) gene (21q21) (AD1),
(ii) >160 mutations in the presenilin 1 (PSEN1)g e n e
(14q24.3) (AD3), and (iii) >10 mutations in the presenilin
2( PSEN2) gene (1q31–q42) (AD4) [9, 24, 25]. PSEN1 and
PSEN2 are important determinants of β-secretase activity
responsible for proteolytic cleavage of APP and NOTCH
receptor proteins. Mendelian mutations are very rare in AD
(1:1000). Mutations in exons 16 and 17 of the APP gene
appear with a frequency of 0.30% and 0.78%, respectively,
in AD patients. Likewise, PSEN1, PSEN2, and microtubule-
associated protein Tau (MAPT) (17q21.1) mutations are
present in less than 2% of the cases. Mutations in these
genes confer speciﬁc phenotypic proﬁles to patients with
dementia: amyloidogenic pathology associated with APP,
PSEN1,andPSEN2mutationsandtauopathyassociatedwith
MATP mutations, representing the two major pathogenic
hypotheses for AD [9, 26–28].
(b) Multiple polymorphic risk variants characterized in
over 200 diﬀerent genes can increase neuronal vulnerability
to premature death [9]. Among susceptibility genes, the
apolipoprotein E (APOE) gene (19q13.2) (AD2) is the most
prevalent as a risk factor for AD, especially in those subjects
harboring the APOE-4 allele, whereas carriers of the APOE-2
allelemightbeprotectedagainstdementia[9].APOE-related
pathogenic mechanisms are also associated with brain aging
and with the neuropathological hallmarks of AD.
In 1993 Allen Roses and coworkers found a clear asso-
ciation between APOE genotypes and AD, demonstrating
that the frequency of the APOE-4 allele was signiﬁcantly
higher in LOAD [29–31]. Since then, many other studies
have conﬁrmed the early ﬁndings of Saunders et al. [30, 31]
and Corder et al. [32], reporting an increased frequency
of the APOE-4 allele in AD and the association of the
APOE-4 allele with LOAD and sporadic forms of AD
[29–34]. APOE-4 may inﬂuence AD pathology interacting
with APP metabolism and Aβ accumulation, enhancing
the hyperphosphorylation of tau protein and NFT forma-
tion, reducing choline acetyltransferase activity, increasing
oxidative processes, modifying inﬂammation-related neu-
roimmunotrophic activity and glial activation, altering lipid
metabolism, lipid transport, and membrane biosynthesis in
sprouting and synaptic remodeling, and inducing neuronal
apoptosis [9, 29–37]. Age-related changes in brain structure
and function have been reported as potential indicators of
premature neurodegeneration [38].
Other genes of this category are included in Table 1.
One of the newest members of the AD gene family is
SORL1, a gene that encodes a mosaic protein with a domain
structure which suggests it is a member of both the vacuo-
lar protein sorting-10 (Vps10) domain-containing receptor
family and the low-density lipoprotein receptor (LDLR).
Inherited variants of the SORL1 neuronal sorting receptor
are associated with late-onset AD. Polymorphisms in two
diﬀerent clusters of intronic sequences within the SORL1
genemayregulatetissue-speciﬁcexpressionofSORL1,whichInternational Journal of Alzheimer’s Disease 3
Table 1: Selected human genes investigated as potential candidate genes associated with dementia and age-related neurodegenerative
disorders [42].
Locus Symbol Aliases Title
1p21.3-p13.1 SORT1 Gp95, NT3 Sortilin
1p31.3 TM2D1 BBP TM2 domain containing 1
1p32 ERI3 PINT1; PRNPIP; MGC2683; FLJ22943 ERI1 exoribonuclease family member 3
1p32.3 ZFYVE9 MADHIP, NSP, SARA, SMADIP Zinc ﬁnger, FYVE domain containing 9
1p33-p31.1 DHCR24 KIAA0018, Nbla03646, SELADIN1, seladin-1 24-dehydrocholesterol reductase
1p34 LRP8 APOER2, HSZ75190, MCI1 Low-density lipoprotein receptor-related
protein 8, apolipoprotein E receptor
1p36.1 ECE1 RP3-329E20.1, ECE Endothelin-converting enzyme 1
1p36.13-q31.3 APH1A RP4-790G17.3, 6530402N02Rik, APH-1, APH-1A,
CGI-78
Anterior pharynx defective 1 homolog A (C.
elegans)
1p36.22 TARDBP RP4-635E18.2, ALS10, TDP-43 TAR DNA-binding protein
1p36.3 MTHFR 5,10-methylenetetrahydrofolate reductase
(NADPH)
1q21 S100A1 S100, S100-alpha, S100A S100 calcium-binding protein A1
1q21.2-q21.3 LMNA
RP11-54H19.1, CDCD1, CDDC, CMD1A, CMT2B1,
EMD2, FPL, FPLD, HGPS, IDC, LDP1, LFP, LGMD1B,
LMN1, LMNC, PRO1
Lamin A/C
1q21.3 CHRNB2 EFNL3, nAChRB2 Cholinergic receptor, nicotinic, beta 2
(neuronal)
1q21-q23 APCS MGC88159, PTX2, SAP Amyloid P component, serum
1q22-q23 NCSTN RP11-517F10.1, APH2, KIAA0253 Nicastrin
1q25 SOAT1 RP11-215I23.1, ACACT, ACAT, ACAT1, RP11-215I23.2,
SOAT, STAT Sterol O-acyltransferase 1
1q25.2-q25.3 PTGS2 COX-2, COX2, GRIPGHS, PGG/HS, PGHS-2, PHS-2,
hCox-2
Prostaglandin-endoperoxide synthase 2
(prostaglandin G/H synthase and
cyclooxygenase)
1q31-q32 IL10 CSIF, IL-10, IL10A, MGC126450, MGC126451, TGIF Interleukin-10
1q31-q42 AD4 AD3L, AD4, PS2, STM2 Presenilin 2 (Alzheimer’s disease 4)
1q32 CR1 C3BR, C4BR, CD35, KN Complement component (3b/4b) receptor 1
(Knops blood group)
1q42-q43 AGT ANHU, FLJ92595, FLJ97926, SERPINA8 Angiotensinogen (serpin peptidase
inhibitor, clade A, member 8)
2p16.3 RTN4
ASY, NI220/250, NOGO, NOGO-A, NOGOC, NSP,
NSP-CL, Nbla00271, Nbla10545, Nogo-B, Nogo-C,
RTN-X, RTN4-A, RTN4-B1, RTN4-B2, RTN4-C
Reticulon 4
2p25 ADAM17 ADAM18, CD156B, CSVP, MGC71942, TACE ADAM metallopeptidase domain 17
2q14 BIN1 AMPH2, AMPHL, DKFZp547F068, MGC10367, SH3P9 Bridging integrator 1
2q14 IL1A IL-1A, IL1, IL1-ALPHA, IL1F1 Interleukin-1-Alpha
2q21.1 KCNIP3 CSEN, DREAM, KCHIP3, MGC18289 Kv channel interacting protein 3, calsenilin
2q21.2 LRP1B LRP-DIT, LRPDIT Low-density lipoprotein-related protein 1B
(deleted in tumors)
2q34 CREB1 CREB, MGC9284 cAMP responsive element binding protein 1
3q25.1-q25.2 CALLA, CD10, MME DKFZp686O16152, MGC126681,
MGC126707, NEP Membrane metalloendopeptidase
3q26.1-q26.2 BCHE CHE1, E1 Butyrylcholinesterase
3q26.2-qter APOD Apolipoprotein D
3q28 SST SMST Somatostatin
4p14-p13 APBB2 DKFZp434E033, FE65L, FE65L1, MGC35575 Amyloid beta (A4) precursor
protein-Binding, family B, member 2
5q15 CAST BS-17, MGC9402 Calpastatin
5q31 APBB3 FE65L2, MGC150555, MGC87674, SRA Amyloid beta (A4) precursor
protein-binding, family B, member 3
5q35.3 DBN1 D0S117E, DKFZp434D064 Drebrin 1
6p12 VEGFA RP1-261G23.1, MGC70609, MVCD1, VEGF, VPF Vascular endothelial growth factor A4 International Journal of Alzheimer’s Disease
Table 1: Continued.
Locus Symbol Aliases Title
6p21.3 AGER DAMA-358M23.4, MGC22357, RAGE Advanced glycosylation end
product-speciﬁc receptor
6p21.3 HFE HFE1, HH, HLA-H, MGC103790, MVCD7,
dJ221C16.10.1 Hemochromatosis
6p21.3 HLA-A DAQB-90C11.16, Aw-68, Aw-69, FLJ26655, HLAA Major histocompatibility complex, class I, A
6p21.3 TNF DADB-70P7.1, DIF, TNF-alpha, TNFA, TNFSF2 T u m o rn e c r o s i sf a c t o r( T N Fs u p e r f a m i l y ,
member 2)
6p22.1 PGDB1 HUCEP-4, SCAND4, dJ874C20.4 PiggyBac transposable element derived 1
6p23 ATXN1 ATX1, D6S504E, SCA1 Ataxin 1
7p21 IL6 BSF2, HGF, HSF, IFNB2, IL-6 Interleukin-6 (interferon, beta 2)
7q21.3 PON1 ESA, MVCD5, PON Paraoxonase 1
7q22 RELN PRO1598, RL Reelin
7q36 AD10 Alzheimer’s disease 10
7q36 NOS3 ECNOS, eNOS Nitric oxide synthase 3 (endothelial cell)
7q36 PAXIP1 CAGF28, CAGF29, FLJ41049, PACIP1, PAXIP1L, PTIP,
TNRC2
PAX-interacting (with
transcription-activation domain) protein 1
8p21-p12 CLU AAG4, APOJ, CLI, KUB1, MGC24903, SGP-2, SGP2,
SP-40, TRPM-2, TRPM2 Clusterin
8p22 CTSB APPS, CPSB Cathepsin B
9p24.1 IL33 C9orf26, DKFZp586H0523, DVS27, NF-HEV, NFEHEV,
RP11-575C20.2 Interleukin 33
9q13-q21.1 APBA1 D9S411E, MINT1, X11, X11A, X11ALPHA Amyloid beta (A4) precursor
protein-binding, family A, member 1
9q31.1 GRIN3A FLJ45414, NMDAR-L, NR3A Glutamate receptor, ionotropic,
N-methyl-D-aspartate 3A
9q33-q34.1 HSPA5 BIP, FLJ26106, GRP78, MIF2 Heat shock 70kDa protein 5
(glucose-regulated protein, 78kDa)
9q34.1 DAPK1 DAPK, DKFZp781I035 Death-associated protein kinase 1
10p13 AD7 Alzheimer’s disease 7
10p15.2 PITRM1 RP11-298E9.1, KIAA1104, MGC138192, MGC141929,
MP1, PreP, hMP1 Pitrilysin metallopeptidase 1
10q AD6 Alzheimer’s disease 6
10q11.2 ALOX5 RP11-67C2.3, 5-LO, 5-LOX, 5LPG, LOG5, MGC163204 Arachidonate 5-lipoxygenase
10q21 TFAM MtTF1, TCF6, TCF6L1, TCF6L2, TCF6L3, mtTFA Transcription factor A, mitochondrial
10q23 CH25H C25H Cholesterol 25-hydroxylase
10q23-q25 IDE RP11-366I13.1, FLJ35968, INSULYSIN Insulin-degrading enzyme
10q23-q25 SORCS1 RP11-446H13.1, FLJ41758, FLJ43475, FLJ44957 Sortilin-related VPS10 domain containing
receptor 1
10q23.32 HECTD2 FLJ16050 HECT domain containing 2
10q24 COX15 COX15 homolog, cytochrome c oxidase
assembly protein (yeast)
10q24 PLAU ATF, UPA, URK, u-PA Plasminogen activator, urokinase
10q24.33 CALHM1 FAM26C, MGC39514, MGC39617 Calcium homeostasis modulator 1
10q24.33 SH3PXD2A FISH, SH3MD1 SH3 and PX domains 2A
10q26.3 ADAM12 RP11-295J3.5, MCMP, MCMP Mltna, MLTN, MLTNA ADAM metallopeptidase domain 12
11p13 BDNF MGC34632 Brain-derived neurotrophic factor
11p15 APBB1 FE65, MGC: 9072, RIR Amyloid beta (A4) precursor
protein-binding, family B, member 1 (Fe65)
11p15.1 SAA1 MGC111216, PIG4, SAA, TP53I4 Serum amyloid A1
11p15.5 CTSD CLN10, CPSD, MGC2311 Cathepsin D
11q14 PICALM CALM, CLTH, LAP Phosphatidylinositol binding clathrin
assembly protein
11q14.1 GAB2 KIAA0571 GRB2-associated binding protein 2
11q23.2-q23.3 BACE1 ASP2, BACE, FLJ90568, HSPC104, KIAA1149 Beta-site APP-cleaving enzyme 1International Journal of Alzheimer’s Disease 5
Table 1: Continued.
Locus Symbol Aliases Title
11q23.2-q24.2 SORL1 C11orf32, FLJ21930, FLJ39258, LR11, LRP9, SORLA,
SorLA-1, gp250
Sortilin-related receptor, L(DLR class) A
repeats-containing
11q24 APLP2 APPH, APPL2, CDEBP Amyloid beta (A4) precursor-like protein 2
12p11.23-
q13.12 AD5 Alzheimer’s disease 5
12p12.3-p12.1 IAPP AMYLIN, DAP, IAP Islet amyloid polypeptide
12p13.3-p12.3 A2M CPAMD5, DKFZp779B086, FWP007, S863-7 Alpha-2-macroglobulin
12q13-q14 LRP1 A2MR, APOER, APR, CD91, FLJ16451, IGFBP3R, LRP,
MGC88725, TGFBR5
Low-density lipoprotein-related protein 1
(alpha-2-macroglobulin receptor)
13q34 DAOA G72, LG72, SG72 D-amino acid oxidase activator
14q24.3 FOS AP-1, C-FOS FBJ murine osteosarcoma viral oncogene
homolog
14q24.3 PSEN1 AD3, FAD, PS1, S182 Presenilin-1
14q32 RAGE MOK, RAGE1 Renal tumor antigen
14q32.1 CYP46A1 CP46, CYP46 Cytochrome P450, family 46, subfamily A,
polypeptide 1
14q32.1 SERPINA3 AACT, ACT, GIG24, GIG25, MGC88254 Serpin peptidase inhibitor, clade A (alpha-1
antiproteinase, antitrypsin), member 3
15q21.1 CYP19A1 ARO, ARO1, CPV1, CYAR, CYP19, MGC104309,
P-450AROM
Cytochrome P450, family 19, Subfamily A,
polypeptide 1
15q22.2 APH1B APH-1B, DKFZp564D0372, FLJ33115, PRO1328, PSFL,
TAAV688
Anterior pharynx defective 1 homolog B (C.
elegans)
15q11-q12 APBA2 D15S1518E, HsT16821, LIN-10, MGC99508, MGC:
14091, MINT2, X11L
Amyloid beta (A4) precursor
protein-binding, family A, member 2
16p13.3 UBE2I C358B7.1, P18, UBC9 Ubiquitin-conjugating enzyme E2I (UBC9
homolog, yeast)
16q21 CETP HDLCQ10 Cholesteryl ester transfer protein, plasma
16q22 NAE1 A-116A10.1, APPBP1, HPP1, ula-1 NEDD8 activating enzyme E1 subunit 1
17p12-p11.2 COX10
COX10 homolog, cytochrome C oxidase
assembly protein, heme A:
farnesyltransferase (yeast)
17p13 MYH13 MyHC-eo Myosin, heavy chain 13, skeletal muscle
17p13.1 TNK1 MGC46193 Tyrosine kinase, nonreceptor, 1
17q11.2 BLMH BH, BMH Bleomycin hydrolase
17q11.2 MIR144 MIRN144 MicroRNA 144
17q21.1 MAPT DDPAC, FLJ31424, FTDP-17, MAPTL, MGC138549,
MSTD, MTBT1, MTBT2, PPND, TAU Microtubule-associated protein tau
17q21.1 STH MAPTIT, MGC163191, MGC163193 Saitohin
17q21.32 GRN GEP, GP88, PCDGF, PEPI, PGRN Granulin
17q21-q22 GPSC Gliosis, familial progressive subcortical
17q21-q23 APPBP2 HS.84084, KIAA0228, PAT1 Amyloid beta precursor protein
(cytoplasmic tail) binding protein 2
17q23.1 MPO Myeloperoxidase
17q23.3 ACE ACE1, CD143, DCP, DCP1, MGC26566, MVCD3 Angiotensin-I-converting enzyme
(peptidyl-dipeptidase A) 1
17q24.3 BPTF FAC1, FALZ, NURF301 Bromodomain PHD ﬁnger transcription
factor
18q12.1 TTR HsT2651, PALB, TBPA Transthyretin
19p13 PIN1 DOD, UBL5 Peptidylprolyl cis/trans isomerase,
NIMA-interacting 1
19p13.2 AD9 Alzheimer’s disease 9
19p13.2-p13.1 NOTCH3 CADASIL, CASIL Notch homolog 3 (Drosophila)
19p13.3 APBA3 MGC: 15815, X11L2, mint3 Amyloid beta (A4) precursor
protein-binding, family A, member 36 International Journal of Alzheimer’s Disease
Table 1: Continued.
Locus Symbol Aliases Title
19p13.3 GRIN3B NR3B Glutamate receptor, ionotropic,
N-methyl-D-aspartate 3B
19p13.3-p13.2 ICAM BB2, CD54, P3.58 Intercellular adhesion molecule 1
19q13 TOMM40 C19orf1, D19S1177E, PER-EC1, PEREC1, TOM40 Translocase of outer mitochondrial
membrane 40 homolog (yeast)
19q13.1 APLP1 APLP Amyloid beta (A4) precursor-like protein 1
19q13.12 PEN2 MDS033, MSTP064, PEN-2, PEN2 Presenilin enhancer 2 homolog (C. elegans)
19q13.2 APOE AD2, LDLCQ5, LPG, MGC1571 Apolipoprotein E
19q13.2 APOC1 Apolipoprotein C-I
19q13.32 BLOC1S3 BLOS3, FLJ26641, FLJ26676, HPS8, RP Biogenesis of lysosomal organelles
complex-1, subunit 3
19q13.32 EXOC3L2 FLJ36147, MGC16332, XTP7 Exocyst complex component 3-like 2
19q13.3 MARK4 FLJ90097, KIAA1860, MARKL1, Nbla00650 MAP/microtubule aﬃnity-regulating kinase 4
19q13.43 GALP Galanin-like peptide
20p AD8 Alzheimer’s disease 8
20p11.21 CST3 ARMD11, MGC117328 Cystatin C
20p13 PRNP ASCR, CD230, CJD, GSS, MGC26679, PRIP, PrP,
PrP27-30, PrP33-35C, PrPc, prion Prion protein
20q13.31 PCK1 MGC22652, PEPCK-C, PEPCK1, PEPCKC Phosphoenolpyruvate carboxykinase 1
(soluble)
21q21.3 APP AAA, ABETA, ABPP, AD1, APPI, CTFgamma, CVAP,
PN2 Amyloid beta (A4) precursor protein
21q22.3 BACE2 AEPLC, ALP56, ASP1, ASP21, BAE2, CDA13, CEAP1,
DRAP Beta-site APP-cleaving enzyme 2
22q11.21 RTN4R NGR, NOGOR Reticulon 4 receptor
22q11.21 COMT Catechol-O-methyltransferase
directs traﬃcking of APP into recycling pathways. When
SORL1 is underexpressed, APP is sorted into Aβ-generating
compartments leading to amyloid accumulation in neuronal
tissues [39]. As with many other potential AD-related genes,
the association of SORL1 with AD [39, 40] could not be
replicated in other studies [41].
Sorting protein-related receptor with A-type repeats
(SORLA) is a major risk factor in cellular processes leading
to AD. It acts as a sorting receptor for the APP that regulates
intracellular traﬃcking and processing into amyloidogenic-
beta peptides (Aβ). Overexpression of SORLA in neurons
reduces while inactivation of gene expression accelerates
amyloidogenic processing and senile plaque formation.
Brain-derived neurotrophic factor (BDNF) is a major in-
ducer of SORLA that activates receptor gene transcription
through the ERK (extracellular regulated kinase) pathway.
Expression of the receptor is signiﬁcantly impaired in mouse
models with genetic (Bdn(−/−)) or disease-related loss of
BDNF activity in the brain (Huntington’s disease). Exoge-
nous application of BDNF reduced Aβ production in
primary neurons and in the brain of wild-type mice in vivo,
but not in animals genetically deﬁcient for Sorla. According
to these ﬁndings reported by Rohe et al. [43], the beneﬁcial
eﬀects ascribed to BDNF in APP metabolism act through
induction of Sorla which encodes a negative regulator of
neuronal APP processing. The presence of the BDNF Val
allele in itself and in combination with the APOE-4 allele
can be risk factors for AD, Lewy body dementia, and Pick’s
disease [44].
Another interesting gene is DHCR24 (3β-hydroxysterol-
δ-24-reductase) or Seladin-1, a key element in the choles-
terologenic pathway in which the DHCR24 enzyme catalyzes
the transformation of desmosterol into cholesterol [45, 46].
Seladin-1wasoriginallyidentiﬁedasagenewhoseexpression
was downregulated in the AD brain, demonstrating a neuro-
protective eﬀect against neurodegeneration. Recent studies
indicate that Seladin-1/DHCR24 is an LXR (liver X nuclear
hormone receptor) target gene potentially involved in the
regulation of lipid raft formation [45].
Polymorphisms in the cholesteryl ester transfer protein
(CETP)genehavebeenassociatedwithexceptionallongevity
and lower cardiovascular risk, but associations with memory
decline and dementia risk are unclear. Sanders et al. [47]
tested the hypothesis that an SNP at CETP codon 405
(isoleucine to valine V405; SNP rs5882) is associated with
a lower rate of memory decline and lower risk of incident
dementia,includingAD.Comparedwithisoleucinehomozy-
gotes, valine homozygotes had signiﬁcantly slower memory
decline and lower risk of dementia.
Another gene, with potential therapeutic interest as a tau
kinase, might be the GSK3 gene. Analysis of the promoter
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(IVS2-68G>A) occurred at over twice the frequency among
patients with frontotemporal dementia (10.8%) and patients
with AD (14.6%) than in aged healthy subjects (4.1%).
This is the ﬁrst evidence that a gene known to be involved
in tau phosphorylation is associated with risk for primary
neurodegenerative dementias [48].
PromoterpolymorphismsmodulatingHSPA5expression
might also increase susceptibility to AD. Endoplasmic
reticulum chaperone heat shock 70kDa protein 5 (HSP-
A5/GRP78) is known to be involved in APP metabolism and
neuronal death in AD. Of the three major polymorphisms
(−415G/A(rs391957), −370C/T(rs17840761), and −180-
Del/G(rs3216733)), the HSPA5-415G/A and −180Del/G
variantsshowedsigniﬁcantdiﬀerencesbetweenADcasesand
controls. Subjects harboring the −415AA/−180GG genotype
or the −415A/−180G allele might be less susceptible to
developing AD [49].
The rs5952C and rs1568566T alleles of the APOD
rs5952T/C and rs1568566C/T variants increase the risk for
AD, whereas the rs5952T-rs1568566C haplotype reduces it
[50]. ApoD is a lipoprotein-associated glycoprotein which is
increased in the hippocampus and CSF of AD patients [50].
CALHM1 encodes a multipass transmembrane glyco-
protein that controls cytosolic Ca2+ concentrations and Aβ
levels. The CALHM1 P86L polymorphism (rs2986017) has
been associated with AD [51].
Harold et al. [52] undertook a two-stage genome-wide
association study (GWAS) of AD involving over 16,000
individuals and found association with SNPs at two loci
not previously associated with the disease, at the CLU
(Clusterine, APOJ) gene (rs11136000) and 5  to the PICALM
gene (rs3851179). In another GWAS with patients from
France, Belgium, Finland, Italy, and Spain, Lambert et al.
[53] found association with CLU and with the CR1 gene,
encoding the complement component (3b/4b) receptor 1
on chromosome 1 (rs6656401). Jun et al. [54] determined
whether genotypes at CLU, PICALM,a n dCR1 confer risk
for AD and whether risk for AD associated with these
genes is inﬂuenced by APOE genotypes in 7,070 cases with
AD, 3,055 with autopsies, and 8,169 elderly cognitively
normal controls, 1,092 with autopsies, from 12 diﬀerent
studies, including white, African American, Israeli-Arab,
and Caribbean Hispanic individuals. They conﬁrmed in a
completely independent data set that CR1 (rs3818361), CLU
(rs11136000), and PICALM (rs3851179) are AD suscepti-
bility loci in European ancestry populations. Genotypes at
PICALM conferriskpredominantlyin APOE-4-positivesub-
jects. Thus, APOE and PICALM synergistically interact. Two
new loci were identiﬁed to have genome-wide signiﬁcance
for the ﬁrst time: rs744373 near BIN1 and rs597668 near
EXOC3L2/BLOC1S3/MARK4 [55].
Kramer et al. [56] conducted a GWAS to identify genetic
mechanisms that distinguish nondemented elderly with a
heavy NFT burden from those with a low NFT burden. Both
a genotype test, using logistic regression, and an allele test
provided consistent evidence that variants in the RELN gene
are associated with neuropathology in the context of cogni-
tive health. Immunohistochemical data for reelin expression
inAD-relatedbrainregionsaddedsupportfortheseﬁndings.
Reelin signaling pathways modulate phosphorylation of tau,
the major component of NFTs, either directly or through
beta-amyloid pathways that inﬂuence tau phosphorylation.
Upregulation of reelin may be a compensatory response to
tau-related or beta-amyloid stress associated with AD even
prior to the onset of dementia [56]. Aβ induces synaptic dys-
function in part by altering the endocytosis and traﬃcking
of AMPA and NMDA receptors. Reelin is a neuromodulator
that increases glutamatergic neurotransmission by signaling
through the postsynaptic ApoE receptors ApoER2 and
VLDLR and thereby potently enhances synaptic plasticity.
Reelincanpreventthesuppressionoflong-termpotentiation
and NMDA receptors, which is induced by levels of Aβ
comparable to those present in an AD-aﬄicted brain. This
reversal is dependent upon the activation of Src family




A variable-length, deoxythymidine homopolymer (poly-
T) within intron 6 of the TOMM40 gene was found to be
associated with the age of onset of LOAD by Roses et al.
[58]. This result was obtained with a phylogenetic study of
the genetic polymorphisms that reside within the linkage
disequilibrium (LD) block that contains the TOMM40,
APOE,a n dAPOC1 genes from patients with LOAD and
age-matched subjects without disease [59]. These new data
explain the mean age at disease onset for patients with the
APOE4/4 genotype and diﬀerentiate two forms of TOMM40
poly-T polymorphisms linked to APOE, with each form
associated with a diﬀerent age at disease onset distribution.
When linked to APOE3 (encoding the ε3 isoform of APOE),
the longer TOMM40 poly-T repeats (19–39 nucleotides) at
the rs10524523 (hereafter, 523) locus are associated with
earlier age at onset and the shorter TOMM40 523 alleles
(11–16 nucleotides) are associated with later age at onset.
According to Roses [60], the data suggest that the poly-
T alleles are codominant, with the age at onset phenotype
determinedbythetwoinherited523alleles,butwithvariable
expressivity.
Ohe and Mayeda [61] reported that overexpression of
high-mobility group A protein 1a (HMGA1a) causes aber-
rantexon5skippingofthepresenilin-2(PSEN2)pre-mRNA,
whichisalmostexclusively detectedin patientswithsporadic
AD. An electrophoretic mobility shift assay conﬁrmed aber-
rantU1small-nuclear-ribonucleoprotein-particle-(snRNP-)
HMGA1a complex formation (via the U1-70K component),
withRNAcontainingaspeciﬁcHMGA1a-bindingsiteandan
adjacent 5  splice site. The HMGA1a-induced aberrant exon
skipping is caused by impaired dissociation of U1 snRNP
from the 5  splice site, leading to a defect in exon deﬁnition.
Kelley et al. [62] characterized a kindred with a familial
neurodegenerative disorder associated with a mutation in
progranulin (PGRN). PGRN analysis revealed a single
base pair deletion in exon 2 (c.154delA), which caused
a frameshift (p.Thr52HisfsX2) and, therefore, creation of
a premature termination codon and a likely null allele.
In this large kindred, most aﬀected individuals had clin-
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cognitive impairment associated with a mutation in PGRN
and underlying frontotemporal lobar degeneration with
ubiquitin-positive neuronal cytoplasmic and intranuclear
inclusions (FTLD-U). Mutation in the PGRN gene can cause
frontotemporal dementia (FTD9). Yu et al. [63] identiﬁed
58 genetic variants that included 26 previously unknown
changes. 24 variants appeared to be pathogenic, including
eight novel mutations. The frequency of PGRN mutations
was 6.9% of all FTD-spectrum cases, 21.4% of cases with a
pathological diagnosis of FTLD-U, 16.0% of FTD-spectrum
cases with a family history of a similar neurodegenerative
disease, and 56.2% of cases of FTLD-U with a family history.
Haploinsuﬃciency of PGRN is the predominant mechanism
leading to FTD.
Polymorphismswithinthepromoterregion ofthevascu-
lar endothelial growth factor (VEGF) gene might elevate the
riskforAD.InaTunisianpopulation,Smachetal.[64]found
that the distribution of genotype and allele frequencies of the
VEGF (−2578C/A)and(−1154G/A)polymorphismsdidnot
diﬀer signiﬁcantly between AD and control groups. In the
subgroup of APOE-4 carriers, the −2578A was observed to
be signiﬁcantly higher in the AD patients than in the control
individuals.
Endothelin-converting enzyme (ECE-1) is also a candi-
date AD susceptibility gene. Individuals homozygous for the
C-338Apolymorphism(AA)withintheECE1genepromoter
region are at reduced risk of developing late-onset AD
(LOAD).Afurtherpolymorphism,T-839G,ispresentwithin
the ECE1 promoter region but there is no signiﬁcant associ-
ation between T-839G and LOAD; however, the combined
839T/338A haplotype is associated with decreased risk of
LOAD, suggesting that the ECE1 338A allele is protective
against LOAD in a Chinese population [65].
Downregulation of somatostatin (SST) expression in the
human brain during early stages of aging may lead to an
elevation in the steady-state levels of Aβ and therefore may
be involved in AD progression. Alterations in the SST gene
might alter its expression or function and also play a role in
thepathogenesisofsporadicAD(SAD).C/Tpolymorphisms
(rs4988514) were screened in the 3  untranslated region of
the SST gene. The C allele of the rs4988514 polymorphism
had an increased incidence in the SAD group compared to
thecontrolgroupintheChinesepopulation.Insubjectswith
the APOE-4 allele, the presence of both the CC genotype and
the C allele of this polymorphism was elevated in the SAD




The receptor for advanced glycation end products
(RAGE) is associated with several pathological states includ-
ing AD pathology, while its soluble form (sRAGE) acts
as a decoy receptor. Li et al. [67] studied an SNP in the
RAGE gene (G82S; rs2070600) and an SNP associated with
increased ligand aﬃnity of RAGE. Analysis of a Chinese
cohort showed a higher prevalence of the RAGE 82S allele
a n dG S+S Sg e n o t y p ei nE O A Dp a t i e n t s .R A G Ec o n t r i b u t e s
to transport of Aβ from the cell surface to the intracellular
space. Pretreatment of cultured neurons from wild-type
mice with neutralizing antibody to RAGE and neurons from
Rage knockout mice displayed decreased uptake of Aβ and
protection from Aβ-mediated mitochondrial dysfunction
[68].
The TAR-DNA-binding protein (TDP-43) has been pos-
tulated as the disease protein in amyotrophic lateral sclerosis
and frontotemporal lobar dementia with ubiquitin-positive
inclusions. TDP-43 may also play a role in the pathogenesis
of AD. Shibata et al. [69] identiﬁed an association between
a speciﬁc haplotype (G-A-A-G) of the TDP-43 gene and risk
for AD.
Immune dysfunction and aberrant inﬂammatory reac-
tions are present in AD neuropathology. Neurons express
enzymessuchascyclooxygenases(COXs)and5-lipoxygenase
(5-LO), which are considered important in inﬂammatory
cells. It has been suggested that COX-2 and 5-LO enzymes
may play a role in the pathophysiology of AD. A signiﬁcant
diﬀerence was observed in the distribution of the −765G
COX-2 and −1708A 5-LO alleles between AD cases and
controls. COX-2 −765G and 5-LO −1708A alleles were over-
represented in AD patients and underrepresented in controls
[70]. The HLA-A∗01 variant might also be associated with
AD[71].SNPsintheregulatoryregionsofthecytokinegenes
for tumor necrosis factor alpha (TNF-alpha), interleukin-
(IL-)6,andIL-10 havebeen suggestedto inﬂuencethe risk of
ADwithconﬂictingresults.Heterozygotes(AG)orcombined
genotype (AG + AA) for IL-10 −1082 was associated with an
approximately two-fold increase in the risk of AD. Carriers
of A alleles of both TNF-alpha-308 and IL-10 −1082 had 6.5
times higher risk for AD in comparison with noncarriers.
Concomitant presence of both mutant TNF-alpha-308 A
and IL-6 −174 C alleles raised three-fold the AD risk,
whereas there was no notable risk for AD aﬄicted by IL-6
−174 polymorphism alone [72, 73]. Interleukin-33 (IL-33),
a newly described member of the IL-1 family, is located on
chromosome 9p24, a chromosomal region of interest in AD.
Three intronic rs1157505, rs11792633, and rs7044343 SNPs
within IL-33 have been reported to be associated with risk of
AD in Caucasian and Chinese populations [74].
Aromatase gene polymorphisms have also been asso-
ciated with AD [75]. Polymorphisms in genes encoding
amyloid-beta-peptide- (Aβ-) degrading enzymes neprilysin
(NEP) and insulin-degrading enzyme (IDE) individually
aﬀect the susceptibility to AD among the Finnish population
[76]. Nicastrin (NCSTN) is a type I transmembrane glyco-
protein and an essential component of γ-secretase, a multi-
protein complex required for the production of the mature
form of Aβ. Overexpression of wild-type NCSTN increases
Aβ production, indicating that the strict regulation of
NCSTN expression may play a fundamental role in the
pathogenesis of AD. Zhong et al. [77] investigated the eﬀect
ofanSNP(rs10752637)locatedinthepromoterregionofthe
NCSTN gene, on NCSTN promoter activity. The distribu-
tionsofthers10752637genotypesandallelefrequencieswere
signiﬁcantly diﬀerent between the AD and control groups,
with the −922T allele signiﬁcantly associated with the occur-
rence of AD. Reporter assays indicated that the rs10752637
−922T allele had a signiﬁcantly increased promoter activity
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probably inﬂuence the expression of NCSTN, and this may
be an inﬂuencing factor during the pathogenesis of AD.
The FISH (ﬁve SH3 domains) adapter protein and
ADAM12 (a disintegrin and metalloprotease) may mediate
the neurotoxic eﬀect of Aβ. Both genes are located on chro-
mosome 10, within a region linked to AD (for SH3PXD2A)
or nearby (for ADAM12). Two variants of these genes
(rs3740473 for SH3PXD2A and rs11244787 for ADAM12)
have been associated with increased risk for developing
AD, but these ﬁndings could not be conﬁrmed in diﬀerent
populations [78].
Paraoxonase 1 (PON1) L55M and Q192R genetic vari-
ants might aﬀect individual susceptibility to environmental
events, such as exposure to cholinesterase inhibitors. The
L55M Met allele exerts an AD risk-enhancing eﬀect only in
men, whereas both men and women carrying the M55M/-
Q192Q genotype exhibit increased survival and later age of
onset. These genetic variants are also individually and sig-
niﬁcantly associated, sometimes in opposite directions for
both genders, with beta-amyloid levels, senile plaque accu-
mulation,andcholineacetyltransferaseactivityinbrainareas
[79].
Liu et al. [80] studied the potential association of poly-
morphisms in NMDA receptor subunits NR3A and NR3B,
encoded by the GRIN3A and GRIN3B genes, with AD, on the
basis that memantine, an N-methyl-D-aspartate (NMDA)
receptor antagonist, may provide some clinical beneﬁt in
ADpatients.TwoSNPs,3104G/A(rs10989563)and3723G/A
(rs3739722), in the GRIN3A gene, and two GRIN3B gene
polymorphisms, 1210C/T (rs4807399) and 1730C/T (rs224-
0158), were analyzed. Upon genotyping of the exonic poly-
morphism in the GRIN3A gene, the G allele was present
at a higher rate than the A allele at position 3723 in AD
patients compared with normal groups. Three haplotypes
(designated Ht1-3) were identiﬁed from these two polymor-
phisms (3104G/A and 3723G/A), and the distribution of Ht2
(AG) diﬀered between AD patients and controls. The two
GRIN3B gene variants 1210C/T and 1730C/T did not show
association with AD. These observations suggest that the
genetic variation of the NR3A, but not NR3B, subunit of the
NMDA receptor may be a risk factor for AD pathogenesis
among the Taiwanese population. Di Maria et al. [81]
reported that the occurrence of delusions and hallucinations
in AD is associated with variations in the G72/DAOA gene
(rs2153674), which is supposed to play a key role in the
glutamate pathway regulated through the NMDA receptors.
Mart´ ınez et al. [82] studied the inﬂuence of the catechol-
O-methyltransferase (COMT) gene (polymorphism Val158
Met) as a risk factor for AD and mild cognitive impairment
of the amnesic type (MCI) and its synergistic eﬀect with
APOE variants in the Basque Country. Neither COMT alleles
nor genotypes were independent risk factors for AD or MCI;
however, the high activity genotypes (GG and AG) showed a
synergistic eﬀect with the APOE-4 allele, increasing the risk
of AD.
Peptidyl-prolyl isomerase NIMA-interacting 1 (PIN1)
plays a signiﬁcant role in the brain and is implicated in
numerous cellular processes related to AD and other neuro-
degenerative conditions. Analysis of 18 PIN1 common
polymorphisms and their haplotypes in EOAD, LOAD, and
FTD individuals in comparison with the control group did
not reveal their contribution to disease risk. In six unrelated
familial AD patients four novel PIN1 sequence variants were
detected. The c.58+64C>T substitution identiﬁed in three
patients was located in an alternative exon. In silico analysis
suggestedthatthisvarianthighlyincreasesapotentialaﬃnity
for a splicing factor and introduces two intronic splicing
enhancers. In the peripheral leukocytes of one living patient
carrying the variant, a 2.82-fold decrease in PIN1 expression
was observed [83].
Alzheimer’s and prion diseases are neurodegenerative
disorders characterized by the abnormal processing of Aβ
peptide and prion protein (PrPC), respectively. PrPC may
play a critical role in the pathogenesis of AD. PrPC interacts
with and inhibits the β-secretase BACE1, the rate-limiting
enzyme in the production of Aβ.P r P C was also identiﬁed
as a receptor for Aβ oligomers, and the expression of PrPC
appears to be controlled by the amyloid intracellular domain
(AICD). PrPC exerts an inhibitory eﬀect on BACE1 to
decrease both Aβ and AICD production, and the AICD
upregulatesPrPC expression,thusmaintainingtheinhibitory
eﬀect of PrPC on BACE1. According to Kellett and Hooper
[84], this feedback loop is disrupted in AD, and the increased
level of Aβ oligomers binds to PrPC and prevents it from
regulating BACE1 activity. It is also likely that PRNP gene
mutations contribute to AD pathogenesis [9]. HECTD2
maps to 10q and has been implicated in susceptibility to
human prion disease. A HECTD2 intronic tagging SNP, rs1-
2249854 (A/T), has been studied in AD. The rs12249854
minor allele (A) frequency was higher (5.8%) in AD as
compared to controls (3.9%). No signiﬁcant diﬀerence was
seen in minor allele frequency in the presence or absence of
the APOE-4 allele. According to these results, it appears that
the common haplotypes of HECTD2, tagged by rs12249854,
are not associated with susceptibility to LOAD [85].
Ubiquitin-conjugating enzyme E2I (Ubc9) ligates small
ubiquitin-related modiﬁer (SUMO) to target proteins,
resulting in changes of their localization, activity, or stability.
Sumoylation of APP was reported to be associated with
decreased levels of Aβ aggregates, suggesting that sumoyla-
tion may play a role in the pathogenesis of AD. Ahn et al.
[86] investigated the association between genetic variations
of Ubc9 gene (UBE2I) and LOAD in Koreans. The genotype
distribution of a polymorphism in intron 7 (rs761059)
diﬀered between AD cases and controls and one haplotype
(ht2 CAGAG) was found in 14.0% of the AD patients and
in 11.1% of the controls. Stratiﬁcation by the APOE-4 allele
gave no signiﬁcant diﬀerence between the groups. When the
samples were stratiﬁed by gender, the genotypes of two SNPs
(rs8052688, rs8063) were signiﬁcantly associated with the
risk of MCI among women.
To gain insights into the evolution of the regulatory
mechanisms of the aged brain, Persengiev et al. [87]c o m -
pared age-related diﬀerences in microRNA (miRNA) expres-
sion levels in the cortex and cerebellum of humans, chim-
panzees, and rhesus macaques on a genome-wide scale. In
contrast to global miRNA downregulation, a small subset of
miRNAs was found to be selectively upregulated in the aging10 International Journal of Alzheimer’s Disease
brain of all three species. miR-144 appeared to be associated
with the aging progression. miR-144 plays a central role in
regulating the expression of ataxin 1 (ATXN1), a gene which
is associated with spinocerebellar ataxia type 1 (SCA1).
miRNA activity, including miR-144, -101, and -130 process-
ing, was increased in the cerebellum and cortex of SCA1
and Alzheimer’s patients relative to healthy aged brains.
The activation of miRNA expression in the aging brain
might serve to reduce the cytotoxic eﬀect of polyglutamine
expandedATXN1 andthederegulationofmiRNAexpression
might be a risk factor for neurodegeneration. Bettens et
al. [88] also obtained evidence for association between
rs179943, an intronic SNP in ATXN1 at 6p22.3, and AD.
The cholesterol transporter ATP-binding cassette trans-
porter A1 (ABCA1) moves lipids onto apolipoproteins
including ApoE. Donkin et al. [89] reported that in amyloid
mouse models of AD, ABCA1 deﬁciency exacerbates amyloi-
dogenesis, whereas ABCA1 overexpression ameliorates amy-
loid load, suggesting a role for ABCA1 in Aβ metabolism.
Agonists of liver X receptors (LXRs), including GW3965,
induce transcription of several genes including ABCA1 and
ApoE,r e d u c eA β levels, and improve cognition in AD mice.
Treatment of APP/PS1 mice with GW3965 increased ABCA1
and ApoE protein levels. ABCA1 was observed to require
signiﬁcantly elevated ApoE levels in brain tissue and CSF
upon GW3965 treatment. APP/PS1 mice treated with either
2.5mg/kg/d or 33mg/kg/d of GW3965 showed a clear trend
toward reduced amyloid burden in hippocampus and whole
brain, whereas treated APP/PS1 mice lacking ABCA1 failed
to display reduced amyloid load in whole brain and showed
trends toward increased hippocampal amyloid. Treatment
of APP/PS1 mice with either dose of GW3965 completely
restored novel object recognition (NOR) memory to wild-
type levels, which required ABCA1. These results reported
by Donkin and coworkers suggest that ABCA1 contributes
to several beneﬁcial eﬀects of the LXR agonist GW3965 in
APP/PS1 mice.
The phospholipid transfer protein (PLTP) reduces phos-
phorylation of tau in human neuronal cells. Patients with
AD have signiﬁcantly higher levels of PLTP in brain tissue
andsigniﬁcantlylowerPLTP-mediatedphospholipidtransfer
activity in cerebrospinal ﬂuid. PLTP also aﬀects ApoE secre-
tion from glial cells. Kuerban et al. [90] investigated whether
SNPsofthePLTP geneareassociatedwithADintheJapanese
population and found no genetic association between PLTP
and AD.
Genome-wide association studies (GWASs) in AD high-
light over two dozen novel potential susceptibility loci
beyond the well-established APOE association, including
GAB2 (GRB2-associated binding protein 2), galanin-like
peptide (GALP), piggyBac transposable element derived 1
(PGBD1), tyrosine kinase, non-receptor 1 (TNK1), and at
leastthreereplicatedlociinhithertouncharacterizedgenom-
ic intervals on chromosomes 14q32.13, 14q31.2, and 6q24.1,
probablyimplicatingtheexistenceofnovelADgenesinthese
regions [91].
(c) Diverse mutations located in mitochondrial DNA
(mtDNA) through heteroplasmic transmission can inﬂuence
aging and oxidative stress conditions, conferring phenotypic
heterogeneity [9, 92]. The human presequence protease
(hPreP) was recently shown to be the major mitochondrial
Aβ-degrading enzyme. Genetic variation in the hPreP gene
PITRM1 has been investigated by Pinho et al. [93]. No
genetic association was found between any of the SNPs and
the risk for AD; however, functional analysis of four nonsyn-
onymous SNPs in hPreP revealed a decreased activity com-
pared to wild-type hPreP. Using Aβ, the presequence of ATP
synthase F1β subunit and a ﬂuorescent peptide as substrates,
the lowest activity was observed for the hPreP(A525D)
variant, corresponding to rs1224893, which displayed only
20–30% of wild-type activity. Genetic variation in the
hPreP gene PITRM1 might contribute to mitochondrial dys-
function in AD.
Recent data suggest the possible contribution of heme
deﬁciency to the progressive derangement of mitochondria
in the AD brain; shortage of heme, and particularly of heme-
a, actually leads to loss of mitochondrial cytochrome c oxi-
dase(COX),abnormalproductionofreactiveoxygenspecies,
and altered amyloid precursor protein metabolism. Diﬀer-
ences in the amount and/or functioning of COX assembly
subunits 10 (COX10) and 15 (COX15), the key enzymes
involved in heme-a biosynthesis, could be linked to varia-
tions of the individual risk to develop AD. Vitali et al. [94]
analyzed mRNA expression in the hippocampus from AD
patients and controls, as well as nucleotide variations in
DNAsequencesinAD.COX15mRNAwassigniﬁcantlymore
abundant in the cerebral tissue of AD patients, and the
IVS-178G>AN SNP in COX10 and the c+1120C>TS N Pi n
COX15 were signiﬁcantly less represented in AD, suggesting
a possible protective role.
JapaneseADpatientsareassociatedwiththehaplogroups
G2a, B4c1, and N9b1. Takasaki [95] compared mitochon-
drial haplogroups of AD patients with those of other classes
of Japanese (centenarians, Parkinson’s disease (PD), type 2
diabetes mellitus (T2D), and nonobese young males). The
four classes of people were associated with the following
haplogroups: Japanese centenarians with M7b2, D4b2a, and
B5b; PD patients with M7b2, B4e, and B5b; T2D patients
with B5b, M8a1, G, D4, and F1; Japanese healthy nono-
bese young males with D4g and D4b1b. The haplogroups
of the AD patients diﬀered from those of the other four
categories.
Santoro et al. [96] applied for the ﬁrst time a high-
resolution analysis to investigate the possible association
betweenmtDNA-inheritedsequencevariationandADin936
AD patients and 776 cognitively assessed normal controls
fromcentralandnorthernItaly.Amongover40mtDNAsub-
haplogroupsanalyzed,theyfoundthatsub-haplogroupH5is
a risk factor for AD, particularly in females, independently of
the APOE genotype. The H5a subgroup of molecules, har-
boring the 4336 transition in the tRNAGln gene, was about
threefold more represented in AD patients than in controls
(2.0% versus 0.8%), and it might account for the increased
frequency of H5 in AD patients (4.2% versus 2.3%). The
complete resequencing of the 56 mtDNAs belonging to H5
revealed that AD patients showed a trend towards a higher
number of sporadic mutations in tRNA and rRNA genes
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Gene Interactions. Although APP and PSEN mutations are
considered causative factors for AD, the total number of
mutations identiﬁed in the APP, PSEN1, and PSEN2 genes
account for less than 3% of the cases with AD, clearly indi-
catingthatneurodegenerationassociatedwithADpathogen-
esis cannot be exclusively attributed to APP/PSEN-related
cascades (amyloid hypothesis). Alterations in the ubiquitin-
proteasome system and biochemical disarray in the chap-
erone machinery are alternative and/or complementary
pathogenic events potentially leading to defects in protein
synthesis, folding, and degradation with subsequent confor-
mational changes, aggregation, and accumulation in cyto-
toxic deposits [4, 9]. A more plausible explanation would
seem to be that multiple susceptibility SNPs with a very sub-
tlegeneticvariationcooperativelycontribute,inconcertwith
environmental factors and concomitant CNS vulnerability,
to premature neurodegeneration in dementia.
We have compared the distribution and frequency of
major polymorphic variants of diﬀerent genes potentially
associated with AD (i.e., APOE, PSEN1, A2M-V1001, A2M-
I/D, ACE, FOS, AGT-235, AGT-174, eNOS3-E298D, eNOS3-
27bpTR, CETP,a n dMTHFR) in the general population, in
adults (>45 years) with no family history of dementia, and in
patients with dementia, and could not ﬁnd any signiﬁcant
diﬀerences among the three groups except in the case of
the APOE gene, which exhibits a clear accumulation of
APOE-3/4 and APOE-4/4 genotypes (overload of the APOE-
4 allele) in AD cases [5]. If we consider that a genetic
variation higher than 2% could be of signiﬁcant value, then
severalpolymorphismsclearlydiﬀerinADascomparedwith
the other two population clusters, including the PSEN1-
1/2, ACE-D/D, ACE-I/I, CEPT-B1/B1, and MTHFR-T/T
polymorphisms [5].
Defective functions of genes associated with longevity
may inﬂuence premature neuronal survival, since neurons
are potential pacemakers deﬁning lifespan in mammals
[9, 97]. Hypothalamic expression of CREB-binding protein
(CBP) and CBP-binding partner special AT-rich sequence
binding protein 1 (SATB-1) is highly correlated with lifespan
across ﬁve strains of mice, and expression of these genes
decreases with age and diabetes in mice. In a transgenic
Aβ42 model of AD, cbp-1 RNAi prevents protective eﬀects
of bacterial dilution (bDR) and accelerates Aβ42-related
pathology. Consistent with the function of CBP as a histone
acetyltransferase, drugs that enhance histone acetylation
increase lifespan and reduce Aβ42-related pathology, pro-
tective eﬀects completely blocked by cbp-1 RNAi. Other
factorsimplicated in lifespan extension are also CBP-binding
partners,suggestingthatCBP constitutesacommonfactorin
themodulationoflifespananddiseaseburdenbyDRandthe
insulin/IGF1 signaling pathway [98].
ADpatientshavebeenreportedtohaveshortertelomeres
in peripheral blood leukocytes (PBLs) than age-matched
control subjects. However, it is unclear if PBL telomere
length reﬂects brain telomere length, which might play a
more direct role in AD pathogenesis. Lukens et al. [99]
examined the correlation between PBL and cerebellum
telomere length in AD patients. The PBL and cerebellum
telomere lengths were directly correlated in individuals
with AD. Nonetheless, cerebellum telomere lengths were
not signiﬁcantly diﬀerent in AD patients and age-matched
control subjects. Reduced PBL telomere length in AD might
not reﬂect reduced telomere length in bulk brain tissue but
may be a marker of changes in a subset of brain tissues
or other tissues that aﬀect the pathogenesis of AD. Zekry
et al. [100] evaluated the usefulness of telomere length
alone or combined with APOE polymorphism in diagnosing
mild cognitive impairment (MCI) and in diﬀerentiating
AD from vascular and mixed dementia. Although APOE-4
was associated with dementia, no signiﬁcant diﬀerences in
telomere length were found among patients with diﬀerent
types of dementia. The combination of telomere length and
APOE-4 did not confer a signiﬁcantly higher dementia risk
[100].
3. FunctionalGenomics
Over 80% of the genes that conform the structural archi-
tecture of the human genome are expressed in the brain in
a time-dependent manner along the lifespan. The cellular
complexity of the CNS (with 103 diﬀerent cell types) and
synapses (with each of the 1011 neurons in the brain
havingaround103-104 synapseswithacomplexmultiprotein
structure integrated by 103 diﬀerent proteins) requires a very
powerful technology for gene expression proﬁling, which is
still in its very early stages and is not devoid of technical
obstacles and limitations [101]. Transcripts of 16,896 genes
have been measured in diﬀerent CNS regions. Each region
possesses its own unique transcriptome ﬁngerprint which
is independent of age, gender, and energy intake. Less than
10% of genes are aﬀected by age, diet, or gender, with
most of these changes occurring between middle and old
age. Gender and energy restriction have robust inﬂuences
on the hippocampal transcriptome of middle-aged animals.
Prominent functional groups of age- and energy-sensitive
genes are those encoding proteins involved in DNA damage
responses, mitochondrial and proteasome functions, cell
fate determination, and synaptic vesicle traﬃcking. The
systematic transcriptome dataset provides a window into
mechanisms of neuropathogenesis and CNS vulnerability
[102].
Functional genomics studies have demonstrated the
inﬂuence of many genes on AD pathogenesis and phenotype
expression. The study of genotype-phenotype correlations is
essential for the evaluation of the actual impact of speciﬁc
polymorphic variants of a particular gene on the clinical
manifestation of the disease and/or biological markers
reﬂecting the disease condition or diﬀerent biological states
of the individual. Mutations in the APP, PSEN1, PSEN2,
and MAPT genes give rise to well-characterized diﬀerential
neuropathological and clinical phenotypes of dementia [9,
24, 25]. APP mutations are associated with AD1, early-onset
progressive autosomal recessive dementia, early-onset AD
with cerebral amyloid angiopathy, and hereditary amyloi-
dosis with cerebral hemorrhage Dutch type, Italian type, or
Iowa type. PSEN1 mutations are associated with the pheno-
types of familial AD3, familial AD3 with unusual plaques,12 International Journal of Alzheimer’s Disease
familial AD with spastic paraparesis and unusual plaques,
familial AD with paraparesis and apraxia, frontotemporal
dementia, Pick’s disease, and dilated cardiomyopathy. MAPT
mutations are associated with frontotemporal dementia,
frontotemporal dementia with parkinsonism, Pick’s disease,
progressivesupranuclearpalsy,progressiveatypicalsupranu-
clear palsy, tauopathy, and respiratory failure [9].
Transgenic animals also reproduce to some extent the
neuropathological hallmarks of AD in a sequential manner.
The triple transgenic mouse model of AD (3xTg-AD) har-
bors three AD-related loci: human PS1M146V, human APP-
swe, and human MAPTP301L. These animals develop both
amyloid plaques and NFT-like pathology in a progressive
and age-dependent manner in hippocampus, amygdala, and
cerebral cortex, the main foci of human AD neuropathology.
The evolution of AD-related transgene expression, amyloid
deposition, tau phosphorylation, astrogliosis, and microglia
activation throughout the hippocampus, entorhinal cortex,
primarymotorcortex,andamygdalaovera26-monthperiod
has been immunohistochemically documented. Intracellu-
lar Aβ accumulation is the earliest of AD-related patholo-
gies to be detectable, followed temporally by phospho-tau,
extracellular Aβ, and ﬁnally paired helical ﬁlament and
NFT pathology [103]. In the same model, a decrease in
neurogenesisdirectlyassociatedwiththepresenceofamyloid
plaques and an increase in the number of Aβ contain-
ing neurons in the hippocampus has been demonstrated
[104].
Diﬀerent APOE genotypes also confer speciﬁc pheno-
typic proﬁles to AD patients. Some of these proﬁles may
add risk or beneﬁt when the patients are treated with
conventional drugs, and in many instances the clinical
phenotype demands the administration of additional drugs
whichincreasethecomplexityoftherapeuticprotocols.From
studies designed to deﬁne APOE-related AD phenotypes
[4–9, 37, 97, 105–114], several conﬁrmed conclusions can
be drawn: (i) the age at onset is 5–10 years earlier in
approximately 80% of AD cases harboring the APOE-4/4
genotype; (ii) the serum levels of ApoE are lowest in APOE-
4/4, intermediate in APOE-3/3 and APOE-3/4, and highest
in APOE-2/3 and APOE-2/4; (iii) serum cholesterol levels are
higher in APOE-4/4 than in the other genotypes; (iv) HDL-
c h o l e s t e r o ll e v e l st e n dt ob el o w e ri nAPOE-3 homozygotes
than in APOE-4 allele carriers; (v) LDL-cholesterol levels
are systematically higher in APOE-4/4 than in any other
genotype; (vi) triglyceride levels are signiﬁcantly lower in
APOE-4/4;(vii)nitricoxidelevelsareslightlylowerinAPOE-
4/4; (viii) serum Aβ levels do not diﬀer between APOE-4/4
and the other most frequent genotypes (APOE-3/3, APOE-
3/4); (ix) blood histamine levels are dramatically reduced in
APOE-4/4 as compared with the other genotypes; (x) brain
atrophy is markedly increased in APOE-4/4 > APOE-3/4 >
APOE-3/3; (xi) brain mapping activity shows a signiﬁcant
increase in slow wave activity in APOE-4/4 from early stages
of the disease; (xii) brain hemodynamics, as reﬂected by
reduced brain blood ﬂow velocity and increased pulsatility
and resistance indices, is signiﬁcantly worse in APOE-4/4
(and in APOE-4 carriers, in general, as compared with
APOE-3 carriers); (xiii) lymphocyte apoptosis is markedly
enhanced in APOE-4 carriers; (xiv) cognitive deterioration
is faster in APOE-4/4 patients than in carriers of any other
APOE genotype; (xv) occasionally, in approximately 3–8%
of the AD cases, the presence of some dementia-related
metabolicdysfunctions(e.g.,iron,folicacid,andvitaminB12
deﬁciencies) accumulates more in APOE-4 carriers than in
APOE-3carriers;(xvi)somebehavioraldisturbances(bizarre
behaviors and psychotic symptoms), alterations in circadian
rhythm patterns (e.g., sleep disorders), and mood disorders
(anxietyanddepression)areslightlymorefrequentinAPOE-
4 carriers; (xvii) aortic and systemic atherosclerosis is also
more frequent in APOE-4 carriers; (xviii) liver metabolism
and transaminase activity also diﬀer in APOE-4/4 with
respect to other genotypes; (xix) blood pressure (hyperten-
sion) and other cardiovascular risk factors also accumulate
in APOE-4; (xx) APOE-4/4 are the poorest responders to
conventional drugs. These 20 major phenotypic features
clearly illustrate the biological disadvantage of APOE-4
homozygotes and the potential consequences that these
patients may experience when they receive pharmacological
treatment [4–7, 9, 28, 37, 97, 105–118].
4. Dementia PhenotypeandBiomarkers
The phenotypic features of the disease represent the
biomarkers to be modiﬁed with an eﬀective therapeutic
intervention. Important diﬀerences have been found in
the AD population as compared with healthy subjects in
diﬀerent biological parameters, including blood pressure,
glucose, cholesterol, and triglyceride levels, transaminase
activity, hematological parameters, metabolic factors, thy-
roid function, brain hemodynamic parameters, and brain
mapping activity [4, 5, 9, 97, 105, 108–111]. Blood pressure
values, glucose levels, and cholesterol levels are higher in
AD than in healthy elderly subjects. Approximately 20%
of AD patients are hypertensive, 25% are diabetics, 50%
are hypercholesterolemic, and 23% are hypertriglyceridemic.
Over 25% of the patients exhibit high GGT activity, 5–10%
show anemic conditions, 30–50% show an abnormal cere-
brovascular function characterized by poor brain perfusion,
and over 60% have an abnormal electroencephalographic
pattern, especially in frontal, temporal, and parietal regions,
as revealed by quantitative EEG (qEEG) or computerized
mapping[5,9,105].Signiﬁcantdiﬀerencesarecurrentlyseen
between females and males, indicating the eﬀect of gender
on the phenotypic expression of the disease. In fact, the
prevalence of dementia is 10–15% higher in females than
in males from 65 to 85 years of age. All these parameters
are highly relevant when treating AD patients because some
of them reﬂect a concomitant pathology that also needs
therapeutic consideration. They can also represent general
biomarkers together with regional brain atrophy and perfu-
sion and cognitive function, which may serve as therapeutic
outcome measures. Other biomarkers of potential interest
include cerebrospinal ﬂuid (CSF) and peripheral levels of
Aβ42, protein tau, histamine, interleukins, and some other
candidate markers [5, 119, 120]. In proteomic studies,
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in neuropathologically conﬁrmed AD, nondemented (ND)
elderly controls, and non-AD dementias (NADDs). Markers
selected included apolipoprotein A-1 (ApoA1), hemopexin
(HPX), transthyretin (TTR), pigment epithelium-derived
factor (PEDF), Aβ1–40, Aβ1–42, total tau, phosphorylated
tau, α-1 acid glycoprotein (A1GP), haptoglobin, zinc α-
2 glycoprotein (Z2GP), and apolipoprotein E (ApoE). The
concentrations of Aβ1–42, ApoA1, A1GP, ApoE, HPX, and
Z2GP diﬀered signiﬁcantly among AD, ND, and NADD
subjects. The CSF concentrations of these three markers
distinguished AD from ND subjects with84% sensitivity and
72% speciﬁcity, with 78% of subjects correctly classiﬁed. By
comparison, using Aβ1–42 alone gave 79% sensitivity and
61% speciﬁcity, with 68% of subjects correctly classiﬁed.
For the diagnostic discrimination of AD from NADD, only
the concentration of Aβ1-42 was signiﬁcantly related to
diagnosis, with a sensitivity of 58% and a speciﬁcity of 86%
[121].
5. Therapeutic Strategies in Dementia
Modern therapeutic strategies in AD are addressed to
interfering with the main pathogenic mechanisms po-
tentially involved in AD. Major pathogenic events (drug
targets) and their respective therapeutic alternatives include
the following: genetic defects, β-amyloid deposition, tau-
related pathology, apoptosis, neurotransmitter deﬁcits, neu-
rotrophic deﬁcits, neuronal loss, neuroinﬂammation, oxida-
tive stress, calcium dysmetabolism, neuronal hypometabo-
lism, lipid metabolism dysfunction, cerebrovascular dys-
function, neuronal dysfunction associated with nutritional
and/or metabolic deﬁcits, and a miscellany of pathogenic
mechanisms potentially manageable with diverse classes of
chemicals or biopharmaceuticals [4, 5, 9, 37, 97, 105–112,
115]. Since the early 1980s, the neuropharmacology of AD
was dominated by the acetylcholinesterase inhibitors, repre-
sented by tacrine, donepezil, rivastigmine, and galantamine
[2, 3, 122]. Memantine, a partial NMDA antagonist, was
introduced in the 2000s for the treatment of severe dementia
[123], and the ﬁrst clinical trials with immunotherapy, to
reduce amyloid burden in senile plaques, were withdrawn
d u et os e v e r eA D R s[ 124, 125]. During the past few years
no relevant drug candidates have been postulated for the
treatment of AD, despite the initial promises of β-a n dγ-
secretase inhibitors [4, 126, 127]. However, assuming that
the best treatment for AD is neuronal death prevention
prior to the onset of the disease, novel therapeutic options
and future candidate drugs for AD might be a new
generation of anti-amyloid vaccines, such as DNA Aβ42
trimer immunization [128], heterocyclic indazole derivatives
(inhibitors of the serum- and glucocorticoid-inducible-
kinase 1 (SGK1)) [129], NSAID-like compounds [130], IgG-
single chain Fv fusion proteins [131], Hsp90 inhibitors and
HSP inducers [132], inhibitors of class I histone deacetylases
[133], some phenolic compounds [134], agonists of the
peroxisome proliferator-activated receptor-gamma (PPAR-
gamma)[ 135], microRNAs [136], and gene silencing (RNAi)
[137].
6. Pharmacogenetics of AD-Related Genes
Over 500 studies reported during the past two decades have
postulated the potential involvement of APOE in dementia
and other CNS disorders [9]. The distribution and frequency
of APOE genotypes (Figure 1)h a v eb e e ni n v e s t i g a t e di n3 1 5
Spanish controls with no family history of neuropsychiatric
disorders and in patients with anxiety, depression, psychosis,
stroke, Alzheimer’s disease, Parkinson’s disease, attention-
deﬁcit hyperactivity disorder, migraine, epilepsy, vascular
dementia, vascular encephalopathy (with hypertension, dia-
betes, or dyslipidemia), multiple sclerosis, cerebrovascular
insuﬃciency, brain tumors (glioma, astrocytoma, glioblas-
toma, and meningioma), cranial nerve neuropathy (facial
palsy and trigeminal neuralgia), mental retardation, and
posttraumatic brain injury syndrome (Figure 1). The dis-
tribution of APOE genotypes in the Iberian peninsula is
as follows: APOE-2/2 0.32%, APOE-2/3 7.3%, APOE-2/4
1.27%,APOE-3/371.11%,APOE-3/418.41%,andAPOE-4/4
1.59% (Figure 1). There is a clear accumulation of APOE-4
carriers among patients with AD (APOE-3/4 30.30%; APOE-
4/4 6.06%) (P<0.001) and vascular dementia (APOE-3/4
35.85%, APOE-4/4 6.57%) (P<0.001) as compared to
controls. The distribution and frequencies of APOE geno-
t y p e si nA Da l s od i ﬀer from those of patients with anxiety
(P<0.001), depression (P<0.001), psychosis (P<0.005),
migraine (P<0.03), vascular encephalopathy (P<0.001),
and posttraumatic brain injury syndrome (P<0.03).
Signiﬁcant diﬀerences are also present between vascular
dementia and anxiety (P<0.001), depression (P<0.001),
psychosis (P<0.001), migraine (P<0.002), vascular
encephalopathy (P<0.001), and posttraumatic brain injury
syndrome (P<0.008) (Figure 1).
T h ep h a r m a c o g e n o m i c so fA Di ss t i l li nav e r yp r i m i t i v e
stage. In over 100 clinical trials for dementia, APOE has been
used as the only gene of reference for the pharmacogenomics
of AD [5, 7, 9, 105, 112, 113, 138, 139]. Several studies
indicate that the presence of the APOE-4 allele diﬀerentially
aﬀects the quality and extent of drug responsiveness in
AD patients treated with cholinergic enhancers (tacrine,
donepezil, galantamine, and rivastigmine), neuroprotective
compounds (nootropics), endogenous nucleotides (CDP-
choline), immunotrophins (anapsos), neurotrophic factors
(cerebrolysin), rosiglitazone, or combination therapies [5–
7, 9, 105, 112, 113, 138, 140]; however, controversial results
are frequently found due to methodological problems, study
design, and patient recruitment in clinical trials.
APOE-4 carriers show a less signiﬁcant therapeutic
response to tacrine (60%) than patients with no APOE-
4 [141]. The frequency of APOE-4 alleles was higher in
responders to a single oral dose of tacrine [142]. About 80%
of APOE-4(−) AD patients showed marked improvement
after 30 weeks of treatment with tacrine, whereas 60% of
APOE-4(+)carriershadapoorresponse[141].Othersfound
no diﬀerences after 6 months of treatment with tacrine
among APOE genotypes, but after 12 months the CIBIC
scores revealed that APOE-4 carriers had declined more than
the APOE-2 and APOE-3 patients, suggesting that a faster
rate of decline was evident in the APOE-4 patients, probably14 International Journal of Alzheimer’s Disease
Figure 1: Distribution and frequency of APOE genotypes in patients with CNS disorders. C: controls; ANX: anxiety; DEP: depression; PSY:
psychotic disorders; STR: stroke; AD: Alzheimer’s disease; PAR: Parkinson’s disease; ADHD: attention-deﬁcit hyperactivity disorder; MIG:
migraine; EPI: epilepsy; VD: vascular dementia; VE: vascular encephalopathy; MS: multiple sclerosis; CVI: cerebrovascular insuﬃciency; BT:
brain tumors; CNN: cranial nerve neuropathies; MR: mental retardation; PTBS: posttraumatic brain injury syndrome. Source: R. Cacabelos.
CIBE Database. EuroEspes Biomedical Research Center, Institute for CNS Disorders, Coru˜ na, Spain.
reﬂecting that APOE-4 inheritance is a negative predictor of
treatment of tacrine in AD [143]. It has also been shown
that the APOE genotype may inﬂuence the biological eﬀect
of donepezil on APP metabolism in AD [144]. Prospective
studies with galantamine in large samples of patients in
Europe [145] and in USA [146] showed no eﬀect of APOE
genotypes on drug eﬃcacy, but a retrospective study with a
small number of AD cases in Croatia showed the intriguing
result of 71% responders to galantamine treatment among
APOE-4homozygotes[147].MacGowanetal.[148]reported
that gender is likely to be a more powerful determinant of
outcome of anticholinesterase treatment than APOE status
in the short term. In contrast, other studies do not support
the hypothesis that APOE and gender are predictors of the
therapeutic response of AD patients to tacrine or donepezil
[149, 150]. Petersen et al. [151] showed that APOE-4 carriers
exhibited a better response to donepezil. Similar results have
been found by Bizzarro et al. [152]; however, Rigaud et al.
[150] did not ﬁnd any signiﬁcant diﬀerence between APOE-
4-related responders and nonresponders to donepezil. An
APOE-related diﬀerential response has also been observed
in patients treated with other compounds devoid of acetyl-
cholinesterase inhibiting activity (CDP-choline, anapsos)
[153, 154] suggesting that APOE-associated factors may
inﬂuence drug activity in the brain either directly acting
on neural mechanisms or indirectly inﬂuencing diverse
metabolic pathways [155].
In long-term open clinical trials with a multifactorial
treatment, APOE-4/4 carriers are the worst responders [5–
7, 9, 105, 112, 113]. With a similar therapeutic protocol,
PSEN1-1/1 homozygotes are the worst responders and
PSEN1-2/2 carriers are the best responders [5]. Signiﬁcant
ACE-related therapeutic responses to multifactorial treat-
m e n t sh a v ea l s ob e e nr e p o r t e d[ 5, 6]. Among ACE-I/D vari-
ants, ACE-D/D patients were the worst responders and ACE-
I/D carriers were the best responders, with ACE-I/I showing
an intermediate positive response [5, 6]. ACE-related bio-
chemical and hemodynamic phenotypes have been studied
in patients with AD [4, 9, 97]. ACE-I/I patients tend to be
younger than ACE-I/D or ACE-D/D patients at the time of
diagnosis and also to show a more severe cognitive dete-
rioration. Serum ApoE, total cholesterol, LDL-cholesterol,International Journal of Alzheimer’s Disease 15
HDL-cholesterol, nitric oxide, histamine, and ACE levels
are higher in ACE-I/I carriers than in patients with the
other genotypes; in contrast, serum triglyceride and VLDL
levels are notably lower in ACE-I/I patients compared to
patients harboring the ACE-I/D or ACE-D/D genotypes,
whereas Aβ levels do not show any clear diﬀerence among
ACE-relatedgenotypes.Cerebrovascularfunctiontendstobe
worse in ACE-D/D, with lower brain blood ﬂow velocities
andhigherpulsatilityandresistanceindices,thaninACE-I/D
(intermediate cerebrovascular hemodynamics) or ACE-I/I
(almost normal cerebrovascular function) [4, 6, 9, 97]. Low
triglyceride levels may facilitate cerebrovascular function.
ACE-I/I patients with the highest cholesterol levels are the
worst in mental performance. These data might suggest
an association of poor cerebrovascular function with ACE-
D/D and ACE-I/D and an association of alterations in lipid
metabolism with ACE-I/I [4, 6].
BothAPOE andACE variantsalsoaﬀectbehaviorandthe
modiﬁcation of behavioral changes (mood and anxiety) in
dementia after nonpsychotropic pharmacological treatment
[4, 6, 9, 105, 113]. At baseline, all APOE variants show
similar anxiety and depression rates, except the APOE-4/4
carrierswhodiﬀered from the rest in signiﬁcantly lower rates
of anxiety and depression. Remarkable changes in anxiety
were found among diﬀerent APOE genotypes. Practically
all APOE variants responded with a signiﬁcant diminution
of anxiogenic symptoms, except patients with the APOE-
4/4 genotype, who only showed a slight improvement. The
best responders were APOE-2/4 > APOE-2/3 > APOE-3/3 >
APOE-3/4 carriers. The potential inﬂuence of APOE variants
on anxiety and cognition in AD does not show a clear
parallelism,suggestingthatothermorecomplexmechanisms
are involved in the onset of anxiety in dementia. Concerning
depression, all APOE genotypes improved their depressive
symptoms with treatment except those with the APOE-4/4
genotype, which worsen along the treatment period. The
best responders were APOE-2/4 > APOE-2/3 > APOE-3/3 >
APOE-3/4, and the worst responder was APOE-4/4 [4, 6].
Patients with each one of the 3 ACE-I/D indel variants
were equally anxiogenic and depressive at baseline and all
of them responded favorably to the multifactorial protocol
by gradually reducing anxiety and depressive symptoms over
the 12-month treatment period. The best responders were
ACE-I/D > ACE-D/D > ACE-I/I. Depressive symptoms were
also similarly improved in all ACE-I/D variants. The best
responders were ACE-I/D > ACE-D/D > ACE-I/I. Compar-
atively, the worst responders among ACE-I/D variants were
carriersoftheACE-I/I genotype, which were also the poorest
responders in anxiety and cognition [4, 6, 115].
The combination of APOE and ACE polymorphic vari-
ants in bigenic clusters yielded diﬀerent anxiety and depres-
sion patterns at baseline and after one year of treatment.
The most anxiogenic patients at baseline were those with the
23DD, 44ID, and 34II genotypes, and the least anxiogenic
patients were those harboring the 23II, 44DD, and 23ID
genotypes. The most depressive clusters at baseline were
those harboring the 23DD, 33ID, and 33II genotypes, with a
clearaccumulationofAPOE-3/3carriersinthesegroups,and
theleastdepressiveclusterswerethoserepresentedbycarriers
of the 23II, 44ID, and 23ID genotypes. All bigenic clusters
showed a positive anxiolytic and antidepressive response
to the multifactorial treatment, except 44DD carriers who
exhibited the worst response [4, 6, 115].
APOE inﬂuences liver function and CYP2D6-related
enzyme activity probably via regulation of hepatic lipid
metabolism. It has been observed that APOE may inﬂuence
liver function and drug metabolism by modifying hepatic
steatosis and transaminase activity. There is a clear correla-
tion between APOE-related TG levels and GOT, GPT, and
GGT activities in AD [4, 6]. Both plasma TG levels and
transaminase activity are signiﬁcantly lower in AD patients
harboring the APOE-4/4 genotype, probably indicating (i)
that low TG levels protect against liver steatosis and (ii) that
the presence of the APOE-4 allele inﬂuences TG levels, liver
steatosis, and transaminase activity. Consequently, it is very
likely that APOE inﬂuences drug metabolism in the liver
through diﬀerent mechanisms, including interactions with
enzymes such as transaminases and/or cytochrome P450-
r e l a t e de n z y m e se n c o d e di ng e n e so ft h eC Y Ps u p e r f a m i l y
[4, 6, 115].
When APOE and CYP2D6 genotypes are integrated in
bigenic clusters and the APOE+CYP2D6-related therapeutic
response to a combination therapy is analyzed in AD
patients, it becomes clear that the presence of the APOE-4/4
genotype is able to convert pure CYP2D6∗1/∗1 EMs into full
PMs, indicating the existence of a powerful inﬂuence of the
APOE-4 homozygous genotype on the drug-metabolizing
capacity of pure CYP2D6-EMs. In addition, a clear accumu-
lation of APOE-4/4 genotypes is observed among CYP2D6
P M sa n dU M s[ 5].
From these studies we can conclude the following. (i)
Most studies with acetylcholinesterase inhibitors indicate
that the presence or absence of the APOE-4 allele inﬂuences
the therapeutic outcome in patients with AD. (ii) Multi-
factorial treatments combining neuroprotectants, endoge-
nous nucleotides, nootropic agents, vasoactive substances,
cholinesterase inhibitors, and NMDA antagonists associated
with metabolic supplementation on an individual basis
adapted to the phenotype of the patient may be useful to
improve cognition and to slow down disease progression
in AD. (iii) The therapeutic response in AD seems to be
genotype-speciﬁc under diﬀerent pharmacogenomic condi-
tions. (iv) In monogenic-related studies, patients harboring
the APOE-4/4 genotype are the worst responders. (v) APP,
PSEN1, and PSEN2 mutations inﬂuence the therapeutic
response in AD. (vi) In trigenic-related studies (APOE +
PSEN1 + PSEN2) the best responders are those patients car-
rying the 331222-, 341122-, 341222-, and 441112-genomic
clusters.(vii)Theworstrespondersinallgenomicclustersare
patients with the 441122 + genotype. (viii) The interaction
of several AD-related genes seems to be determinant for
drug eﬃcacy and safety. (ix) APOE-CYP2D6 interactions
might inﬂuence the therapeutic response in AD via changes
in lipid metabolism and liver function. (x) APOE may also
interact with PSEN1, ACE, A2M, and other genes to regulate
the eﬀect of drugs on cognition and behavioral changes in
dementia. (xi) The APOE-4/4 genotype seems to accelerate
neurodegeneration anticipating the onset of the disease by16 International Journal of Alzheimer’s Disease
Figure 2: APOE-related therapeutic response to a multifactorial therapy in patients with dementia. Cognitive performance (MMSE Score).
Tb: basal MMSE score prior to treatment; Tt: MMSE score after 3 months of treatment in the total sample. E2/3b: basal MMSE score in
APOE-2/3 carriers; E2/3t: MMSE score after treatment in APOE-2/3 carriers; E2/4b: Basal MMSE score in APOE-2/4 carriers; E2/4t: MMSE
score after treatment in APOE-2/4 carriers; E3/3b: basal MMSE score in APOE-3/3 carriers; E3/3t: MMSE score after treatment in APOE-3/3
carriers; E3/4b: basal MMSE score in APOE-3/4 carriers; E3/4t: MMSE score after treatment in APOE-3/4 carriers; E4/4b: basal MMSE score
in APOE-4/4 carriers; E4/4: MMSE score after treatment in APOE-4/4 carriers.
5–10 years, and, in general, APOE-4/4 carriers show a faster
disease progression and a poorer therapeutic response to all
available treatments than any other polymorphic variant.
(xii) Pharmacogenomic studies using monogenic, bigenic,
trigenic, tetragenic, or polygenic clusters as a harmonization
procedure to reduce genomic heterogeneity in clinical trials
are very useful in order to widen the therapeutic scope of
limited pharmacological resources [4–7, 9, 97, 105–115].
7.APOE-RelatedTherapeutic
Response to a Multifactorial Therapy in
Alzheimer’sDisease
Patients with dementia (N = 765, age: 69.44 ± 9.15 years,
range:50–96years;466females,age:69.18±9.19years,range:
50–96 years; 299 males, age: 69.85 ±9.09 years, range: 50–91
years; P<0.01) received for three months a multifactorial
therapyintegratedbyCDP-choline(500mg/day,p.o.),Nicer-
goline (5mg/day, p.o.), Sardilipin (E-SAR-94010) (LipoEsar)
(250mg, t.i.d.), and Animon Complex (2 capsules/day), a
nutraceutical compound integrated by a puriﬁed extract of
Chenopodium quinoa (250mg), ferrous sulphate (38.1mg
equivalent to 14mg of iron), folic acid (200μg), and
vitamin B12 (1μg) per capsule (RGS: 26.06671/C). Patients
with chronic deﬁciency of iron (<35μg/mL), folic acid
(<2.5ng/mL), or vitamin B12 (<150pg/mL) received an
additional supplementation of iron (80mg/day), folic acid
(5mg/day), and B complex vitamins (B1 15mg/day; B2
15mg/day; B6 10mg/day; B12 10μg/day; nicotinamide 50
mg/day), respectively, to maintain stable levels of serum iron
(50–150μg/mL), folic acid (5–20ng/mL), and vitamin B12
levels (500–1,000pg/mL) in order to avoid the nega-
tive inﬂuence of all these metabolic factors on cogni-
tion [6, 114]. Patients with hypertension (>150/85mmHg)
received Enalapril (20mg/day). The frequency of APOE
genotypes was APOE-2/3 7.97%; APOE-2/4 1.18%; APOE-
3/3 58.95%; APOE-3/4 27.32%; and APOE-4/4 4.58%
(Figure 2). Blood pressure, psychometric assessment (Mini-
MentalStateExamination(MMSE);ADAS;HamiltonRating
Scale-Depression (HAM-D); Hamilton Rating Scale-Anxiety
(HAM-A)),andblood parameters(glucose,totalcholesterol,
HDL-cholesterol, LDL-cholesterol, triglyceride, iron, folate,
vitamin B12, and TSH, T4) were evaluated at baseline and
after 3 months of treatment [42].
Systolic (P<0.0002) and diastolic blood pressure (P<
0.001),cognitivefunction(asassessedbyMMSE,20.51±6.51
versus 21.45 ± 6.95, P<0.0000000001; ADAS-Cog, 22.94 ±International Journal of Alzheimer’s Disease 17
Figure 3: APOE-related systolic blood pressure response to a multifactorial therapy in patients with dementia. Tb: basal systolic blood
pressure (SBP) prior to treatment; Tt: SBP after 3 months of treatment in the total sample. E2/3b: basal SBP in APOE-2/3 carriers; E2/3t:
SBP after treatment in APOE-2/3 carriers; E2/4b: basal SBP in APOE-2/4 carriers; E2/4t: SBP after treatment in APOE-2/4 carriers; E3/3b:
basal SBP in APOE-3/3 carriers; E3/3t: SBP after treatment in APOE-3/3 carriers; E3/4b: basal SBP in APOE-3/4 carriers; E3/4t: SBP after
treatment in APOE-3/4 carriers; E4/4b: basal SBP in APOE-4/4 carriers; E4/4: SBP after treatment in APOE-4/4 carriers.
13.87 versus 21.23 ± 12.84, P<0.0001; ADAS-Non-Cog,
5.26±4.18versus4.15±3.63,P<0.0000000001;ADAS-Total,
27.12 ± 16.93 versus 24.28 ± 15.06, P<0.00009), and mood
(HAM-A, 11.35±5.44 versus 9.79±4.33, P<0.0000000001;
HAM-D, 10.14 ±5.23 versus 8.59 ±4.30, P<0.0000000001)
improved after treatment. Glucose levels did not change.
Total cholesterol levels (224.78±45.53 versus 203.64±39.69
mg/dL, P<0.0000000001), HDL-cholesterol levels (54.11 ±
14.54 versus 52.54 ± 14.86mg/dL, P<0.0001), and LDL-
cholesterollevels(148.15±39.13versus128.89±34.83mg/dL,
P<0.0000000001) were signiﬁcantly reduced, whereas
triglyceride levels increased (111.99 ± 67.14 versus 120.69 ±
67.14mg/dL, P<0.0006) after 3 months of combined treat-
ment. Folate (7.07 ± 3.61 versus 18.14 ± 4.23ng/mL, P<
0.000000001) and vitamin B12 levels (459.65 ± 205.80 versus
689.78±338.82pg/mL,P<0.000000001)alsoincreased,and
bothTSHandT4 levelsremainedunchangedaftertreatment.
The response rate in terms of cognitive improvement was
as follows: 59.74% responders (RRs), 24.44% nonresponders
(NRs), and 15.82% stable responders (SRs) (no change in
MMSE score after three months of treatment). The response
rate in cholesterol levels was very similar: 57.78% RRs,
28.50% NRs, and 13.72% SRs [42].
In this study, the basal MMSE score diﬀered in APOE-
2/3 carriers with respect to APOE-2/4 (P<0.02), APOE-3/4
(P<0.004), and APOE-4/4 carriers (P<0.0009), in APOE-
3/3 versus APOE-3/4 (P<0.0005), and APOE-3/3 versus
APOE-4/4 (P<0.002). The best responders were APOE-3/3
(P<0.0000000001) > APOE-3/4 (P<0.00001) > APOE-4/4
carriers (P<0.05) (Figure 2). Patients harboring the APOE-
2/3 and APOE-2/4 genotypes did not show any signiﬁcant
improvement. The response rate by genotype was the follow-
ing: APOE-2/3: 44.26% RRs, 36.07% NRs, and 19.67% SRs;
APOE-2/4: 55.56% RRs, 44.44% NRs, and 0.0% SRs; APOE-
3/3: 63.42% RRs, 21.06% NRs, and 15.52% SRs; APOE-
3/4: 56.94% RRs, 27.75% NRs, and 15.31% SRs; APOE-4/4:
51.43% RRs, 28.57% NRs, and 20.00% SRs [42].
Systolic blood pressure (SBP) was signiﬁcantly reduced
in patients with the APOE-3/3 (P<0.00007) and APOE-3/4
genotypes (P<0.01), and diastolic blood pressure exhibited
a similar pattern (APOE-3/3, P < 0.005; APOE-3/4, P<
0.01), with no changes in either SBP or DBP in APOE-2/3,
APOE-2/4, and APOE-4/4 carriers (Figure 3)[ 42].
G l u c o s el e v e l st e n d e dt od e c r e a s ei nAPOE-4 allele carri-
ers, but only patients with the APOE-3/4 genotype showed a
signiﬁcant reduction in glucose levels (P<0.02). In contrast,




Basal cholesterol levels were signiﬁcantly diﬀerent in patients
with the APOE-2/3 genotype versus APOE-3/3 (P<18 International Journal of Alzheimer’s Disease
Figure 4: APOE-related changes in total cholesterol levels in patients with dementia treated with E-SAR-94010. Tb: basal total cholesterol
(CHO) levels prior to treatment; Tt: CHO levels after 3 months of treatment in the total sample. E2/3b: basal CHO levels in APOE-2/3
carriers; E2/3t: CHO levels after treatment in APOE-2/3 carriers; E2/4b: basal CHO levels in APOE-2/4 carriers; E2/4t: CHO levels after
treatment in APOE-2/4 carriers; E3/3b: basal CHO levels in APOE-3/3 carriers; E3/3t: CHO levels after treatment in APOE-3/3 carriers;
E3/4b: basal CHO levels in APOE-3/4 carriers; E3/4t: CHO levels after treatment in APOE-3/4 carriers; E4/4b: basal CHO levels in APOE-4/4
carriers; E4/4: CHO levels after treatment in APOE-4/4 carriers.
0.007), versus APOE-3/4 (P<0.001), versus APOE-4/4
(P<0.00002); APOE-2/4 versus APOE-4/4 (P<0.01);
APOE-3/3 versus APOE-4/4 (P<0.005 ); APOE-3/4 versus
APOE-4/4 (P<0.01) (Figure 4)[ 42].
The highest cholesterol levels were seen in APOE-
4/4 > APOE-3/4 > APOE-3/3. All patients showed a
clear reduction in cholesterol levels after treatment with
Sardilipin.ThiswasparticularlysigniﬁcantinAPOE-3/3(P<
0.0000000001) > APOE-3/4 (P<0.00000008) > APOE-
4/4 (P<0.002) > APOE-2/3 (P<0.02) > APOE-2/4
carriers (P: 0.26) (Figure 4) .T h er e s p o n s er a t eb yg e n o -
type was as follows: APOE-2/3: 63.93% RRs, 29.51% NRs,
and 6.56% SRs; APOE-2/4: 44.44% RRs, 22.22% NRs,
and 33.34% SRs; APOE-3/3: 54.32% RRs, 28.16% NRs,
and 17.52% SRs; APOE-3/4: 53.59% RRs, 31.58% NRs,
and 14.83% SRs; APOE-4/4: 65.71% RRs, 20.00% NRs, and
14.29% SRs [42].
HDL-cholesterol levels signiﬁcantly decreased in APOE-
3/3 (P<0.001) > APOE-3/4 (P<0.05), with no signiﬁcant
changes in patients with other genotypes. In contrast, LDL-
cholesterol levels showed identical changes to those observed
in total cholesterol, with similar diﬀerences among geno-
types at baseline and almost identical decreased levels after
treatment (APOE-3/3, P>0.0000000001; >APOE-3/4, P<
0.00001; >APOE-2/3, P<0.0004; >APOE-4/4, P<0.001;
>APOE-2/4, P: 0.31) (Figure 5)[ 42].
Paradoxically, triglyceride levels tended to increase in all
APOE genotypes (APOE-3/3, P < 0.01; >APOE-4/4, P<
0.03; >APOE-2/3, P: 0.12; >APOE-3/4, P:0 . 1 7 ) ,e x c e p ti n
APOE-2/4 carriers, who showed a tendency to decrease.
Basal triglyceride levels were signiﬁcantly lower in APOE-4/4
carriers than in APOE-2/3 (P<0.03) and APOE-3/4 carriers
(P<0.04) [42].
Sardilipin (E-SAR-94010, LipoEsar, LipoSea) is a nat-
ural product extracted from the marine species Sardina
pilchardus,bymeansofnondenaturingbiotechnologicalpro-
cedures [156]. The main chemical compounds of LipoEsar
are lipoproteins (60–80%) whose micelle structure probably
mimics that of physiological lipoproteins involved in lipid
metabolism. In preclinical studies, sardilipin has shown
to be eﬀective in (i) reducing blood cholesterol (CHO),
triglyceride (TG), uric acid (UA), and glucose (Glu) lev-
els, as well as liver alanine aminotransferase (ALT) and
aspartate aminotransferase (AST) activity, (ii) enhancing
immunological function by regulating both lymphocyte and
microglia activity, (iii) inducing antioxidant eﬀects mediated
by superoxide dismutase activity, and (iv) improving cogni-
tive function [97, 156, 157].
According to these results, it appears that the therapeutic
response of patients with dyslipidemia to sardilipin is APOE-
related. The best responders were patients with APOE-3/3
> APOE-3/4 > APOE-4/4. Patients with the other APOE
genotypes (2/2, 2/3,a n d2/4) did not show any hypolipemicInternational Journal of Alzheimer’s Disease 19
Figure 5: APOE-related changes in LDL-cholesterol levels in patients with dementia treated with E-SAR-94010. Tb: basal LDL-cholesterol
(LDL-CHO) levels prior to treatment; Tt: LDL-CHO levels after 3 months of treatment in the total sample. E2/3b: basal LDL-CHO levels in
APOE-2/3 carriers; E2/3t: LDL-CHO levels after treatment in APOE-2/3 carriers; E2/4b: basal LDL-CHO levels in APOE-2/4 carriers; E2/4t:
LDL-CHO levels after treatment in APOE-2/4 carriers; E3/3b: basal LDL-CHO levels in APOE-3/3 carriers; E3/3t: LDL-CHO levels after
treatment in APOE-3/3 carriers; E3/4b: basal LDL-CHO levels in APOE-3/4 carriers; E3/4t: LDL-CHO levels after treatment in APOE-3/4
carriers; E4/4b: basal LDL-CHO levels in APOE-4/4 carriers; E4/4: LDL-CHO levels after treatment in APOE-4/4 carriers.
response to this novel compound [97, 157]. In patients with
dementia, the eﬀects of sardilipin were very similar to those
observed in patients with chronic dyslipidemia, suggesting
that the lipid-lowering properties of sardilipin are APOE-
dependent.
Clinical studies have revealed that sardilipin reduces
blood total cholesterol (T-CHO) (20–30%), Glu (5–10%),
UA (10–15%), TG (30–50%), ALT, and AST, after 1–3
months of treatment at a daily dose of 250–500mg (t.i.d).
The eﬀect on T-CHO is the result of decreasing LDL-CHO
levels and increasing HDL-CHO levels in parallel with an
improvement in hepatic protection reﬂected by reduction
in ALT, AST, and GGT activity, as the result of reducing
liver steatosis. Both LDL and HDL levels are modulated by
dietary, behavioral, and genetic factors [97]. Most of these
therapeuticeﬀectsontheregulationoflipidmetabolismtend
to show an age-dependent pattern and are also associated
with speciﬁc genomic proﬁles in the population. In addition,
sardilipin diminishes the size of xanthelasma plaques by
30–60% after 6–9 months of treatment and speciﬁcally
protectsagainstthehepatotoxicityinducedbystatins.Similar
eﬀects can be observed on atheromatous plaques on the
aortic wall of patients with familial and sporadic dyslipi-
demia/hyperlipidemia. The daily administration of 1,000–
1,500mg/day of E-SAR p.o. for three months tends to reduce
the average size of atherosclerotic plaques on the aortic wall
by 10%. This eﬀect is more signiﬁcant in patients harboring






APOE is a pleiotropic gene with many polymorphic activ-
ities, most of them inﬂuencing AD pathogenesis. In this
regard, the inﬂuence of APOE variants on AD therapeutics
cannot be neglected, especially taking into account that (a)
APOE polymorphic variants by themselves are enough to
modify the therapeutic response to conventional antide-
mentia drugs, (b) ApoE interacts with many receptors and
participates in a large number of metabolic cascades and
signaling pathways, and (c) the presence of the APOE-4 allele
can alter the phenotypic proﬁle of CYP2D6 genotype-related
drug metabolizers and probably also of other cytochrome
P450 enzymes, such as those encoded by the CYP3A5 gene,
whichaﬀectmorethan50%ofthedrugscurrentlyprescribed
in the clinical setting. Moreover, many metabolic pathways
in which APOE participates (e.g., lipid metabolism, APP/Aβ
processing, cardiovascular and cerebrovascular function,20 International Journal of Alzheimer’s Disease
etc.) are involved in pathogenic processes that repre-
sent major risk factors of dementia (e.g., atherosclerosis,
hypercholesterolemia, hypertension, and brain hypoperfu-
sion), which can be potentially predictable and preventable
with therapeutic intervention.
ApoE is a ligand for the 7 identiﬁed mammalian mem-
bers of the evolutionarily conserved low-density lipoprotein
(LDL) receptor family: the low-density lipoprotein receptor
(LDLR), ApoE receptor 2 (ApoER2), the very-low-density
lipoprotein receptor (VLDLR), multiple epidermal growth
factor (EGF) repeat-containing protein (MEGF7), megalin,
LDL-related-protein-1 (LRP1) and LDL-related protein-
1b (LRP1b) [159]. The LDLR family consists of over 10
receptors that function in receptor-mediated endocytosis
and cellular signaling. Together with LDLR itself, the family
includes LRP/LRP1, megalin/LRP2, VLDLR, ApoER2/LRP8,
SORLA-1/LR11, LRP4, LRP5, LRP6, and LRP1B. Most of
the ApoE receptors have been found in the CNS where they
participate in endocytosis, intracellular signaling, synaptic
plasticity, and Aβ metabolism [159]. ApoE receptors have
been suggested to act as clearance mechanisms for Aβ and
have also been implicated in the production of Aβ.L R P
interacts with APP through the intracellular adaptor protein
FE65 or via direct binding to the KPI domain, and its
endocytosis facilitates APP endocytic traﬃcking and Aβ
production [160–162]. SORLA/LR11 alters APP traﬃcking
and APP processing by β-a n dγ-secretases [163–165]. It
has also been suggested that soluble ApoE receptors could
play roles as dominant negative regulators of ApoE, and
thus understanding their generation and actions might
be important for understanding normal and pathological
functions of ApoE in the CNS and in AD [159].
It might be possible that normalization of biological
parameters associated with APOE-related pathogenic path-
ways contributing to brain dysfunction and neurodegen-
eration could be beneﬁcial in terms of prevention and/or
slowing the clinical course of dementia. In this strategic
category we can include the following: (i) lipid metabolism
dyshomeostasis, (ii) APOE-related APP/Aβ processing, (iii)
blood pressure control, (iv) atherogenesis, (v) cerebrovascu-
lar hemodynamics, and (vi) neuroprotection.
Cardiovascular and cerebrovascular disorders associated
with lipid metabolism disturbance and atherosclerosis rep-
resent major risk factors for dementia [119, 120, 166].
Atherosclerosis is the primary cause of heart disease and
stroke in which genetic and environmental factors converge
[167]. More than 90% of patients with dementia older than
70–80 years of age show signs of atherosclerosis in their
arteries and a clear cerebrovascular component in their
dementia process. It is very likely that pure AD is practically
absent in octogenarians in whom the prevalent diagnosis is
vascular or mixed-dementia [119, 120, 166] in which the
APOE-4 allele also accumulates [97, 110, 111, 168].
APOE genotypes directly inﬂuence lipid metabolism and
atherosclerosis. The presence of the APOE-4 allele con-
tributes to the phenotypic manifestation of atherosclerosis,
brain amyloid angiopathy, and cerebral white matter damage
[169]. The size of atheroma plaques in the abdominal and
thoracic aorta of patients with dementia and/or dyslipi-
demia is signiﬁcantly larger in APOE-4 carriers than in
APOE-3 carriers [97, 110, 111]. In addition, the eﬀect of
lipid-lowering agents on atheroma plaques is APOE related
with a more eﬀective response in APOE-3 carriers [97, 110,
111].
Evidence from epidemiological, in vitro,a n din vivo
studies suggests that brain cholesterol may play a role in AD.
The exact nature and magnitude of this role is unknown,
but a number of possibilities have emerged, including
modulation of APP cleavage pathways and Aβ production
and clearance, APOE-mediated cholesterol transport, and
cholesterol eﬄux from the brain [170–172].
Cholesterol is implicated in the production of Aβ, the
primary constituent of senile plaques in the AD brain
[173–177]. In APP transgenic mice, hypercholesterolemia
correlates with increased Aβ levels and more severe amyloid
plaque load [178, 179]. Some retrospective epidemiological
studies indicate that statin therapy might decrease AD risk
[180], but statins do not alter serum Aβ levels [181, 182]a n d
in some cases may worsen cognitive function, increase brain
Aβ load, and/or activate inﬂammatory responses involving
microglia [120, 166, 183]. Some studies have reported an
association between high cholesterol levels and AD risk
[184] and increased brain Aβ1–42 levels [185]. Defective
binding of ApoE to heparan sulfate proteoglycans (HSPGs)
is associated with increased risk of atherosclerosis and AD
probably due to the ineﬃcient clearance of lipoprotein rem-
nants from the liver with negative consequences for neuronal
repair [186]. CYP46∗C (cholesterol 24-hydroxylase) along
with APOE-4 was found associated with higher cognitive
decline in AD and both variants synergistically increase the
risk of AD [187–189]a sw e l la sb r a i na n dC S FA β load [190].
Deﬁciency of the cholesterol transporter ABCA1 produced
by glial cells impairs ApoE metabolism in the CNS [191].
Some studies also indicate that genetic variants of ABCA1
modify AD risk and tau- and Aβ-related pathogenesis [192];
however, other studies have demonstrated that several SNPs
inthemulti-drugresistance(ABCB1)gene(MRD1)(C1236T
inexon12,G2677T/Ainexon21,andC3435Tinexon26)do
not show association with AD [193]; in contrast, ABCA2 has
beenreportedtobeastronggeneticriskfactorforearly-onset
AD [194, 195]. The ATP-binding cassette (ABC) superfamily
consists of membrane proteins that transport a wide variety
of substrates across membranes [196]. ABCA1 and ABCG1
play a pivotal role in the regulation of neuronal cholesterol
to ApoE discs and in suppression of APP processing to
generateAβ.ABCA1isrequiredfornormalbrainApoElevels
and for lipidation of astrocyte-secreted ApoE [197], and the
absence of ABCA1 decreases soluble ApoE levels but does
not diminish Aβ deposition in AD murine models [198],
whereas others have reported increased Aβ deposition in
APP23andPDAPP miceintheabsenceofABCA1,suggesting
that despite substantially lower ApoE levels, poorly lipidated
ApoE produced in the absence of ABCA1 is strongly amy-
loidogenic [199, 200]. ABCA1 protein expression is induced
byligandsofthenuclearhormonereceptorsoftheretinoidX
receptor and liver X receptor family. Treatment of neuroblas-
toma cells with retinoic acid and 22(R)-hydroxycholesterolInternational Journal of Alzheimer’s Disease 21
causes signiﬁcant increases in secreted Aβ40 and Aβ42, and
treatment with a nonsteroidal liver X receptor ligand, TO-
901317, similarly increases Aβ40 and Aβ42 levels, which
can be reduced by RNAi blocking of ABCA1 expression
[201]. Maintenance of an adequate supply of cholesterol is
important for neuronal function whereas excess cholesterol
promotes APP cleavage and generation of toxic Aβ isoforms
[202].ImpairedrecyclingofAPOE-4isassociatedwithintra-
cellular cholesterol accumulation [203]. Cholesterol- and
sphingolipid-rich membrane microdomains are involved
in regulating traﬃcking and processing of APP. In this
metabolic pathway, the amyloidogenic processing of APP
depends on lipid rafts since access of α-a n dβ-secretase to
APP may be determined by dynamic interactions of APP
with membrane lipid microdomains [204]. γ-Secretase is
also located in lipid raft microdomains of post-Golgi and
endosomes that are implicated in APP processing [205].
Methyl-β-cyclodextrin and leptin reduce β-secretase activity
in neuronal cells possibly by altering the lipid composition of
membrane lipid rafts. This phenotype contrasts treatments
with cholesterol and etomoxir, an inhibitor of carnitine-
palmitoyl-transferase-1. Conversely, inhibitors of acetyl CoA
carboxylase and fatty acid synthase mimic the action of
leptin. Leptin is also able to increase ApoE-dependent Aβ
uptake in vitro; thus, leptin can modulate bidirectional
Aβ kinesis, reducing its levels extracellularly. The chronic
administration of leptin to AD-transgenic animals notably
reduces the brain Aβ load [206].
APOE-4 may aﬀect AD risk by conferring high choles-
terol levels and thereby increasing Aβ production [207].
APOE-4 c a r r i e r sw i t hA Dh a v ei n c r e a s e dl e v e l so fb r a i n
and cerebrospinal ﬂuid Aβ a n dh a v em o r ee x t e n s i v ep l a q u e
pathology [208, 209]; however, with a genomic-based
approach, by using an APOE knock-in mouse, which
expresses each human allele under the endogenous regula-
tory elements, on a deﬁned C57BL6/J background, Mann
et al. [207] were able to demonstrate that the presence of
APOE signiﬁcantly increases brain Aβ levels, irrespective of
genotype, this indicating an independent role for APOE in
cholesterol metabolism in the periphery relative to the CNS.
In humans, probably thousands of genes may regulate lipid
metabolism. Some relevant genes, such as APOE (50%),
CETP (28%), LIPC (9%), APOB (8%), and LDLR (5%)
may inﬂuence variation in LDL, and LIPC (53%), CETP
(25%), ABCA1 (10%), LPL (6%), and LDLR (6%) may
inﬂuence the HDL variance [210]. The APOE-2 allele is
associated with the lower and the APOE-4 allele with the
higher total plasma cholesterol and LDL-cholesterol levels
compared with the APOE-3 allele [211]. Individuals with
APOE-2 and APOE-3 reduce plasma cholesterol and LDL-
c h o l e s t e r o ll e v e l sm o r et h a nAPOE-4 individuals treated
with hydroxymethylglutaryl-CoA (HMG-CoA) reductase
inhibitors (statins), gemﬁbrozil and cholestyramine. In con-
trast, APOE-4 carriers might respond better than carriers of
other genotypes to probucol. Perimenopausal women with
APOE-2 or APOE-3 g e n o t y p e sa p p e a rt oi m p r o v ep l a s m a
lipoprotein-lipid proﬁles more than APOE-4 women under
protocols with hormone replacement therapy. Likewise,
APOE-2 and APOE-3 individuals tend to improve plasma
lipid proﬁles with exercise training more than APOE-4
individuals [212]. In an attempt to reverse the ApoE deﬁcit
in AD, Poirier [213] has reported the identiﬁcation and
characterization of several ApoE inducer agents using a low-
throughput screening assay. The old cholesterol-lowering
drug, probucol, led to signiﬁcant increases in CSF ApoE
levels and a decrease of CSF Aβ1-42 with eﬀecton CSF tauor
lipidperoxidelevels[213].Inaprospective,dose-ﬁnding,36-
weektreatmenttrialwithstatins(simvastatinoratorvastatin)
conducted in 39 patients with hypercholesterolemia, Aβ
levels remained unchanged [214]. The Heart Protection
Study Collaborative Group [215] and the Prospective Study
of Pravastatin in the Elderly at Risk (PROSPER) [216]
have both reported that neither simvastatin nor pravastatin
appeared to slow cognitive decline in the elderly during 5
yearsoftreatmentintheHeartProtectionStudyand3.2years
in the PROSPER.
Since ApoE can protect against cardiovascular disease
(e.g., coronary artery disease) via hepatic removal of athero-
genic remnant proteins, sequestration of cholesterol from
vessel walls, and local antioxidant, antiplatelet, and anti-
inﬂammatory actions, it has been postulated that APOE
gene transfer might ameliorate a hyperlipidemic proﬁle and
exert a beneﬁcial eﬀect at lesion sites to prevent or regress
atherosclerosis[217].Usingplasmidvectorsexpressingallelic
human ApoE-2 or ApoE-3 isoforms, Athanasopoulos et
al. [217] demonstrated that skeletal muscle was an eﬀec-
tive secretory platform for ApoE gene augmentation and
that muscle-based expression of ApoE-2 after intramus-
cular plasmid injection in ApoE−/− mice was able to
reduce atherosclerotic lesions in proximal aorta by 20–
30%, with total abolishment of gross dorsal xanthoma
(>5mm diameter) up to 9 months following a single
ApoE-2 plasmid administration. The same group of George
Dickson [218], 2 years later, with an improved technology,
observed an acute regression of advanced and retarda-
tion of early aortic atheroma in immunocompetent ApoE-
deﬁcient mice by administration of a second-generation
(E1-, E3-, polymerase-)adenovirusvectorexpressinghuman
ApoE. Intramuscular injections resulted in low expression
of ApoE and aﬀorded no sustainable protection against
atherogenesis; in contrast, intravenous (liver-directed) injec-
tions into ApoE−/− mice resulted in increased plasma ApoE
levels accompanied by reductions in plasma cholesterol
and normalization of lipoprotein proﬁles. Liver-directed
ApoE gene transfer to these mice retarded progression of
atherosclerosis by 38% during the 70-day study period, with
a progressive decline in ApoE levels and no evoked humoral
immune response [218].
10.CYP2D6-RelatedPharmacogenetics
CYP2D6 is a 4.38 kb gene with 9 exons mapped on 22q13.2.
Four RNA transcripts of 1190–1684bp are expressed in the
brain, liver, spleen, and reproductive system where 4 major
proteins are identiﬁed: CYP2D6-001, 55.73kDa, 497aa;
CYP2D6-002, 50.02kDa, 446aa; CYP2D6-004, 55.19kDa,
494aa; CYP2D6-201, 48.92kDa, 493aa; CYP2D6-202,22 International Journal of Alzheimer’s Disease
48.92kDa, 439aa; CYP2D6–203, 49.65kDa, 443aa. This
protein is a transport enzyme of the cytochrome P450
subfamily IID or multigenic cytochrome P450 superfamily
of mixed-function monooxygenases. The cytochrome P450
proteins are monooxygenases that catalyze many reactions
involved in drug metabolism and synthesis of cholesterol,
steroids, and other lipids. This protein localizes to the
endoplasmic reticulum and is known to metabolize as
many as 25% of commonly prescribed drugs and over
60% of current psychotropics. Its substrates include
debrisoquine, an adrenergic-blocking drug, sparteine and
propafenone, both antiarrhythmic drugs, and amitriptyline,
an antidepressant. The gene is highly polymorphic in the
population; certain alleles result in the poor metabolizer
phenotype,characterizedbyadecreasedabilitytometabolize
theenzymesubstrates.Thegeneislocatednear3cytochrome
P450 pseudogenes on chromosome 22q13.1. In humans
there are 3 CYP2D pseudogenes: CYP2D8P1, CYP2D8P2,
and CYP2D7P1. A frameshift mutation 138delT generates
an open reading frame in the pseudogene, cytochrome
P4502D7 (CYP2D7), and an alternate spliced functional
transcriptofCYP2D7 containingpartialinclusionofintron6
wasidentiﬁedinhumanbrainbutnotinliverorkidneyfrom
the same individual. mRNA and protein of the brain variant
CYP2D7 were detected in 6 of 12 human autopsy brains.
Genotyping revealed the presence of the frameshift mutation
138delT only in those human subjects who expressed the
brain variant CYP2D7. Genomic DNA analysis in normal
volunteers revealed the presence of functional CYP2D7
in 4 of 8 individuals [219]. In the liver, the major organ
involved in drug metabolism, a minor metabolic pathway
mediated by CYP2D6 metabolizes codeine (prodrug) to
morphine (active drug), whereas norcodeine is the major
metabolite. In contrast, when expressed in Neuro2a cells,
brain variant CYP2D7 metabolized codeine to morphine
with greater eﬃciency compared with the corresponding
activity in cells expressing CYP2D6. Morphine binds to
μ-opioid receptors in certain regions of the CNS, such as
periaqueductal gray, and produces pain relief. The brain
variant CYP2D7 and μ-opioid receptor colocalize in neurons
of the periaqueductal gray area in human brain, indicating
that metabolism of codeine to morphine could occur at
the site of opioid action. Tissue-speciﬁc isoforms of P450
generated by alternate splicing, which mediate selective
metabolism of prodrugs within tissues, particularly the
brain, to generate active drugs may play an important role in
drug action and provide newer insights into the genetics of
metabolism [219].
The hepatic cytochrome P450 system is responsible for
the ﬁrst phase in the metabolism and elimination of numer-
ous endogenous and exogenous molecules and ingested
chemicals. P450 enzymes convert these substances into
electrophilic intermediates, which are then conjugated by
phase II enzymes (e.g., UDP glucuronosyltransferases and
N-acetyltransferases) to hydrophilic derivatives that can be
excreted.
The CYP2D6 enzyme is responsible for metabolizing
approximately 25% of pharmaceutical agents. According
to the database of the World Guide for Drug Use and
Pharmacogenomics [220], 982 drugs are CYP2D6 related:
371 drugs are substrates, over 375 drugs are inhibitors, and
18drugsareCYP2D6inducers[220].Inastudytoinvestigate
the elimination routes for the 200 drugs most often sold by
prescription count in the United States, the majority (78%)
of the hepatically cleared drugs were found to be subject to
oxidative metabolism via cytochromes P450 of the families
1, 2, and 3, with major contributions from CYP3A4/5 (37%
of drugs) followed by CYP2C9 (17%), CYP2D6 (15%),
CYP2C19 (10%), CYP1A2 (9%), CYP2C8 (6%), and CYP2B6
(4%). Clinically well-established polymorphic CYPs (i.e.,
CYP2C9, CYP2C19,a n dCYP2D6) were involved in the
metabolism of approximately half of those drugs, including
(in particular) NSAIDs metabolized mainly by CYP2C9,
proton-pump inhibitors metabolized by CYP2C19,a n dβ-
blockers and several antipsychotics and antidepressants
metabolized by CYP2D6 [221].
CYP2D6isoneofthemostimportantenzymescatalyzing
biotransformation of xenobiotics in the human liver. This
enzyme activity shows a high degree of interindividual
variability caused in part by its genetic polymorphism, the
so-called debrisoquine/sparteine polymorphism. There are
141 CYP2D6 allelic variants of which −100C>T, −1023C>T,
−1659G>A, −1707delT, −1846G>A, −2549delA, −2613–
2615delAGA, −2850C>T, −2988G>A, and −3183G>Ar e p -
resent the 10 most important variants [24, 220, 222, 223].
The genetic component inﬂuencing CYP2D6 activity can
be determined by genotyping. However, genotyping alone
is not suﬃcient to accurately predict an individual actual
CYP2D6 activity,asthisisalsoinﬂuencedbyotherfactors.To
determinetheexactactualenzymaticactivity(phenotyping),
adequate probe drugs have to be administered prior to
measurements of these compounds and/or their metabolites
in body ﬂuids. The enzymatic activity is reﬂected by various
pharmacokinetic metrics such as the partial clearance of
a parent compound to the respective CYP2D6-mediated
metabolite or metabolic ratios [224].
The relative catalytic activities (enzyme kinetics) of
three functionally active human CYP2D6 allelic variants,
CYP2D6.1, CYP2D6.10,a n dCYP2D6.17,w e r es y s t e m a t i c a l l y
investigated for their ability to metabolize a structurally
diverse set of clinically important CYP2D6-metabolized
drugs (atomoxetine, bufuralol, codeine, debrisoquine, dex-
tromethorphan, S-ﬂuoxetine, nortriptyline, and tramadol)
and the eﬀects of various CYP2D6 inhibitors (cocaine,
S-ﬂuoxetine, S-norﬂuoxetine, imipramine, quinidine, and
thioridazine) on these three variants. The most signiﬁcant
diﬀerenceobservedwasaconsistentbutsubstrate-dependent
decrease in the catalytic eﬃciencies of cDNA-expressed
CYP2D6.10 and CYP2D6.17 compared with CYP2D6.1,
yielding 1.32 to 27.9 and 7.33 to 80.4% of the eﬃciency of
CYP2D6.1,r e s p e c t i v e l y[ 225].
11.SelectedVariantswithClinicalRelevance
The CYP2D6 locus is highly polymorphic, with diﬀerent
CYP2D6 alleles identiﬁed in the general population show-
ing deﬁcient (PM), normal (EM), intermediate (IM), orInternational Journal of Alzheimer’s Disease 23
increased enzymatic activity (UM) [222, 223]. Most indi-
viduals (>80%) are EMs; however, remarkable interethnic
diﬀerences exist in the frequency of the PM and UM
phenotypes among diﬀerent societies all over the world
[97, 226, 227]. On average, approximately 6.28% of the
world population belongs to the PM category. Europeans
(7.86%), Polynesians (7.27%), and Africans (6.73%) exhibit
the highest rate of PMs, whereas Orientals (0.94%) show the
lowest rate. The frequency of PMs among Middle Eastern
populations, Asians, and Americans is in the range of 2-3%.
CYP2D6 gene duplications are relatively infrequent among
Northern Europeans, but in East Africa the frequency of
alleles with duplication of CYP2D6 is as high as 29% [228].
The most important SNPs with clinical relevance include
the following.
rs1135840:C Y P 2 D 6 -S486T. This SNP is found in the
reduced function of the CYP2D6∗10, ∗17,a n d∗41 haplo-
types with an allelic frequency of C: 0.635 and G: 0.365.
rs59421388:C Y P 2 D 6 -3183G>A and 3271G>A. This variant
is part of the reduced functioning haplotype CYP2D6∗29,
which is found at an estimated allele frequency of 20% in
African Tanzanians.
rs28371725:C Y P 2 D 6 ∗41 and CYP2D6-2988G>A. CYP2D6
2988G>A is an intronic polymorphism that has been shown
to be associated with aberrant splicing of CYP2D6. This
splicing defect leads to the omission of exon 6 from
some of the transcribed RNA and leads to a reduction in
activity. CYP2D6 2988G>A is diagnostic of the haplotype
CYP2D6∗41, which is believed to be responsible for the IM
phenotype in the majority of Caucasians.
rs16947:C Y P 2 D 6 -2850C>T (also named 2938C>T). This is
a common SNP in CYP2D6 and is found in the CYP2D6∗2
haplotype among others. CYP2A6∗2 activity is slightly
reduced but is considered to be in the same extensive
metabolizer (EM) category as CYP2D6∗1.T h ep r e s e n c eo f
CYP2D6 2850C>T and the absence of several others is
diagnostic of the CYP2D6∗2 haplotype.
rs28371720:C Y P 2 D 6 ∗9-CYP2D6:2613–2615delAGA
(2701-2703 delAGA). Causes deletion of amino acid K281.
rs4986774:C Y P 2 D 6 ∗3 and CYP2D6-2549delA (also known
as 2637delA in the literature). This causes a frameshift
mutation that results in a truncated, nonfunctional protein
with an Arg/Gly translation.
rs3892097:C Y P 2 D 6 ∗4 and CYP2D6-1846G>A. CYP2D6
1846G>A (1934G>A) is part of the nonfunctional
CYP2D6∗4 haplotype. This causes a splicing defect that
results in a nonfunctional protein. This variant is responsible
for the majority of the PMs found in Caucasian populations,
and is also found at much lower frequencies in other
p o p u l a t i o n ss u c ha sK o r e a n s .
rs5030655:C Y P 2 D 6 ∗6 and CYP2D6-1707delT. This variant
(CYP2D6-1707delT or 1795delT) causes a frameshift muta-
tion (Trp/Gly) that results in a truncated, nonfunctional
version of CYP2D6. This is the deﬁning SNP for CYP2D6∗6.
Individuals with CYP2D6∗6/∗4, ∗5/∗4, or ∗6/∗6 genotypes
are poor metabolizers of venlafaxine and are more prone
to drug-induced side eﬀects such as nausea, vomiting, and
diarrhea. However, CYP2D6 genotype does not seem to
inﬂuence venlafaxine eﬃcacy.
rs61736512: CYP2D6-1659G>A and 1747G>A. This variant
(CYP2D6 1659G>A or 1747G>A) is rare in Caucasians and
is part of the reduced functioning haplotype CYP2D6∗29,
which is found at an estimated allele frequency of 20% in
African Tanzanians.
rs28371706:C Y P 2 D 6 -1023C>T. CYP2D6-1023C>T (1111
C>T) was ﬁrst identiﬁed when screening for reduced func-
tion alleles in a Zimbabwean population. It was identiﬁed
as being part of the reduced function haplotype CYP2D6∗17
in the African Bantu populations. The presence of CYP2D6
1023C>T (1111C>T) and 2850C>T (2938C>T) is diag-
nostic for CYP2D6∗17. CYP2D6 1023C>T single mutation
exhibited normal function in transfected COS-1 cells, but
when made in combination with another mutation led to
an increased Km (decreased aﬃnity) for bufuralol; when
the substrate was codeine, CYP2D6 1023C>T alone was
suﬃcient to cause an increase in the Km of CYP2D6 for
codeine, suggesting that this mutation exhibits substrate-
speciﬁc eﬀects and may contribute to the reduction in
function of CYP2D6∗17.
rs1065852:C Y P 2 D 6 -100C>T. CYP2D6 100C>T (188C>T)
is part of both the nonfunctional CYP2D6∗4 haplotype and
the reduced function CYP2D6∗10 haplotype. Since CYP2D6
100C>T is present in both a nonfunctional and a reduced
functionhaplotype,itisnotlikelytobethecausativeSNPfor
the lack of function observed with CYP2D6∗4.T h ep r e s e n c e
of CYP2D6 100C>T (188C>T) and the absence of CYP2D6
1846G>A (1934G>A) is diagnostic of CYP2D6∗10. Cells
transfected with CYP2D6 100C>T alone exhibit reduced
function, suggesting that this mutation contributes to the
reduced function of the CYP2D6∗10 allele. Association
studies have examined the role of this variant in contributing
to generalized tonic-clonic seizures (GTCS) seen in epilepsy
and tardive dyskinesia in Chinese schizophrenic patients
[24, 220, 223].
12. Major Haplotypes
CYP2D6-related major haplotypes include the following.
CYP2D6∗1. CYP2D6∗1 is the reference haplotype for
CYP2D6. Together with CYP2D6∗2, this haplotype forms
the group of individuals known as extensive metabolizers or
EMs.CYP2D6∗1isusuallythemajorityalleleforpopulations
of European and African descent. EMs are considered the
norm, and all the other haplotypes are deﬁned as deviations24 International Journal of Alzheimer’s Disease
from CYP2D6∗1. Population frequencies of this haplotype
are African-American: 29–35%; Amerindian: 66%; Cen-
tral/South Asia: 31%; Chinese: 23%; Colombian: 39%; East
Asian: 31%; European: 34%; European Caucasian: 33–36%;
Gabonese: 32%; Ghanaian: 44%; Iberian: 56–72%; Japanese:
42-43%; Malay: 36%; Mexican: 57%; Middle Eastern: 35%;
Native American: 60%; North African: 12%; Oceanian:
72%; Subsaharan African: 24%; Tanzanian: 28–59%; US
Caucasian: 36–40% [220].
CYP2D6∗2. CYP2D6∗2 (CYP2D6-2850C>T) has slightly
r e d u c e df u n c t i o nw h e nc o m p a r e dw i t hCYP2D6∗1.
CYP2D6∗1 and CYP2D6∗2 represent typical EMs. Pop-
ulation frequencies are African-American: 18–27%; Amer-
indian: 19%; Central/South Asian: 29%; Chinese: 2%;
Colombian: 37%; East Asian: 16%; European: 29%; Euro-
pean Caucasian: 22–33%; Gabonese: 44%; Ghanaian: 11%;
Iberian: 2%; Japanese: 9–12%; Mexican: 23%; Middle
Eastern: 25%; Native American: 30%; North African: 28%;
Oceanian: 0%; Subsaharan African: 33%; Tanzanian: 2%; US
Caucasian: 26–37% [220].
CYP2D6∗3. CYP2D6∗3(CYP2D6-2549delA)isacompletely
nonfunctional allele caused by a frameshift mutation that
causes a premature truncation of the CYP2D6 protein.
CYP2D6∗3 is one of several CYP2D6 haplotypes that can
contribute to the phenotypic observation of a poor metab-
olizer (PM). CYP2D6∗3 makes a minor contribution to the
poor metabolizer phenotype in Caucasian populations and
is virtually nonexistent in non-Caucasian populations. Pop-
ulation frequencies are African-American: 0%; Amerindian:
0%; Central/South Asian: 0%; Chinese: 1%; Colombian:
1.2%; East Asian: 0%; Ethiopian: 0%; European: 0%; Euro-
pean Caucasian: 1–4%; Ghanaian: 0%; Iberian: 2%; Inuit:
0%; Mexican: 1%; Middle Eastern: 0%; Native American:
0%; North African: 0%; Oceanian: 0%; Subsaharan African:
0%; Tanzanian: 0%; US Caucasian: 1-2%; Zimbabwean: 0%
[220].
CYP2D6∗4. CYP2D6∗4 (CYP2D6-100C>T and 1846G>A)
is a nonfunctional haplotype that contributes to the majority
of PMs in Caucasian populations. CYP2D6∗4 carriers are at
increased risk when compared to their EM counterparts for
toxicities or lack of eﬃcacy due to CYP2D6 inactivity. Popu-
lationfrequenciesareAfrican-American:6–8%;Amerindian:
4–17%; Central/South Asian: 8%; Chinese: 1%; Colombian:
19.4%; East Asian: 3%; Ethiopian: 1%; European: 17%;
European Caucasian: 12–21%; Ghanaian: 7%; Iberian: 13%;
Inuit: 8%; Japanese: 1%; Malay: 3%; Mexican: 10%; Middle
Eastern: 7%; Native American: 3%; North African: 12%;
Oceanian: 0%; Subsaharan African: 3%; Tanzanian: 1%; US
Caucasian: 18–23%; Zimbabwean: 2-3% [220].
CYP2D6∗5. CYP2D6∗5resultsinanonfunctionalhaplotype
due to a whole gene deletion. This allele contributes to the
PM phenotype pool with a frequency of 1–7% in most
populations. Population frequencies are African-American:
6-7%; Amerindian: 4%; Central/South Asian: 4%; Chinese:
6%; Colombian: 0.8%; East Asian: 6%; Ethiopian: 3%;
European: 3%; European Caucasian: 2–7%; Gabonese: 1%;
Ghanaian: 1%; Iberian: 3%; Japanese: 5-6%; Malay: 5%;
Mexican: 2%; Middle Eastern: 4%; Native American: 1%;
North African: 3%; Oceanian: 1%; Subsaharan African: 6%;
Tanzanian: 6%; US Caucasian: 2–5%; Zimbabwean: 4%
[220].
CYP2D6∗6. CYP2D6∗6 (CYP2D6-1707delT) is a nonfunc-
tional haplotype of CYP2D6. CYP2D6∗6 is caused by a
frameshift mutation that results in a truncated and nonfunc-
tional CYP2D6 protein. CYP2D6∗6 is found primarily in
Caucasian populations. Population frequencies are African-
American: 0%; Amerindian: 1%; Central/South Asian: 0%;
Colombian: 0%; East Asian: 0%; European: 1%; European
Caucasian: 1%; Ghanaian: 0%; Iberian: 3%; Inuit: 8%;
Middle Eastern: 1%; Native American: 0%; North African:
0%; Oceanian: 0%; Subsaharan African: 0%; Tanzanian: 0%;
US Caucasian: 1% [220].
CYP2D6∗9. CYP2D6∗9 (CYP2D6-2613–2615delAGA) is a
reducedfunctionhaplotypecausedbythedeletionofasingle
amino acid; its mRNA lacks a single codon resulting in
deletion of Lys281. This variant probably represents less than
1.5% of all CYP2D6 alleles. The highest frequency is present
among Caucasians of Europe and North America. Popu-
lation frequencies are African-American: 0%; Amerindian:
0%; Central/South Asian: 0%; East Asian: 0%; European:
3%; European Caucasian: 0–2%; Ghanaian: 0%; Malay: 3%;
Middle Eastern: 0%; Native American: 0%; North African:
0%; Oceanian: 0%; Subsaharan African: 0%; Tanzanian: 0%;
US Caucasian: 2-3%; Zimbabwean: 0% [220].
CYP2D6∗10. CYP2D6∗10 (CYP2D6-100C>T) is a reduced
function haplotype very common in populations of Asian
ancestry, especially among Japanese and Malay. Homozy-
gotes of this allele are common and result in the IM
phenotype. IMs are also at risk for adverse events and lack
of eﬃcacy similar to those seen in PMs, although not as
severe,duetotheresidualactivityofCYP2D6∗10.P opulation
frequencies are African-American: 3–8%; Amerindian: 2–
18%; Central/South Asian: 4%; Chinese: 5–7%; East Asian:
4%; Ethiopian: 9%; European: 3%; European Caucasian:
1-2%; Ghanaian: 3%; Iberian: 2–5%; Inuit: 2%; Japanese:
38–41%; Malay: 50%; Mexican: 7%; Middle Eastern: 1%;
Native American: 0%; North African: 0%; Oceanian: 3%;
Subsaharan African: 4%; Tanzanian: 4%; US Caucasian: 2–
8%; Zimbabwean: 0% [220].
CYP2D6∗17. CYP2D6∗17 (CYP2D6-2850C>T and 1023C>
T) is a reduced function allele of CYP2D6. CYP2D6∗17 was
frequently misdiagnosed as CYP2D6∗2 in the early studies of
CYP2D6 genotyping, particularly in populations of African
origin. CYP2D6∗17 carriers show an IM phenotype. The
highest frequency of this haplotype appears in Africans.
PopulationfrequenciesareAfrican-American:15–23%;Cen-
tral/South Asian: 0%; Colombian: 1.7%; East Asian: 0%;
Ethiopian: 1%; European: 0%; European Caucasian: 0%;International Journal of Alzheimer’s Disease 25
Gabonese: 24%; Ghanaian: 28%; Malay: 1%; Mexican: 1%;
Middle Eastern: 2%; Native American: 1%; North African:
8%; Oceanian: 0%; Subsaharan African: 12%; Tanzanian:
17%; US Caucasian: 0%; Zimbabwean: 34% [220].
CYP2D6∗29. CYP2D6∗29 (CYP2D6 2850C>Ta n dCYP2D6
1659G>Aa n dCYP2D6 3183G>A) is a reduced function-
ing haplotype of CYP2D6. This haplotype was originally
discovered in African populations and contributes towards
the IM phenotype of CYP2D6. Population frequencies are
Central/South Asian: 0%; East Asian: 0%; European: 0%;
Middle Eastern: 0%; Native American: 0%; North African:
0%; Oceanian: 0%; Subsaharan African: 7% [220].
CYP2D6∗41. CYP2D6∗41 (CYP2D6-2850C>T and 2988G>
A) is also a reduced functioning haplotype of CYP2D6
that contributes towards the IM phenotype. Popu- lation
frequencies are Central/South Asian: 11%; East Asian: 2%;
European: 7%; Middle Eastern: 17%; Native American: 0%;
North African: 8%; Oceanian: 0%; Subsaharan African: 3%
[220].
CYP2D6-UM. CYP2D6 UM is a generic term used to
indicate multiple CYP2D6 copies (2–13) that cause the
ultrarapid metabolizer (UM) phenotype. Gene duplications
are present in many diﬀerent CYP2D6 haplotypes, includ-
ing CYP2D6∗1, CYP2D6∗2, CYP2D6∗4, CYP2D6∗10,a n d
CYP2D6∗41. These gene copies can cause a lack of eﬃcacy
by quickly metabolizing a parent drug. UMs can suﬀer from
similar problems as PMs, despite having opposite pheno-
types.Forinstance,both canexperiencealackof eﬃcacy,but
in the case of UMs it would be from quickly metabolizing
a parent drug, whereas in the case of PMs it would be
the inability to form an active metabolite. Toxicity can
occur in both haplotypes. UMs would experience toxicities
resulting from a high level of metabolite, whereas the PMs
would experience toxicities resulting from a high level of
parentdrug.PopulationfrequenciesofcombinedCYP2D6∗1
and CYP2D6∗2 haplotypes are African-American: 1–5%;
Amerindian: 3%; Central/South Asian: 1%; Chinese: 1%;
Colombian:1.2%;EastAsian:12%;European:1%;European
Caucasian: 2%; Gabonese: 3%; Iberian: 7%; Middle Eastern:
2%;NativeAmerican:5%;NorthAfrican:7%;Oceanian:5%;
Subsaharan African: 28%; Tanzanian: 14%; US Caucasian:
1% [220, 223].
13. Phenotypes
The classiﬁcation of CYP2D6 phenotypes according to major
haplotypes is as follows.
Extensive Metabolizers (EMs): normal enzyme activity:
CYP2D6∗1, CYP2D6∗2, CYP2D6∗27, CYP2D6∗33, CYP2-
D6∗35, CYP2D6∗39, and CYP2D6∗48.
Intermediate Metabolizers (IMs): decreased enzyme activity:
CYP2D6∗9, CYP2D6∗10, CYP2D6∗17, CYP2D6∗29, CYP2-
D6∗41, CYP2D6∗49, CYP2D6∗50, CYP2D6∗51, CY-
P2D6∗55, CYP2D6∗59, and CYP2D6∗72.
Poor Metabolizers (PMs): no or negligible enzyme activity:
CYP2D6∗3, CYP2D6∗4, CYP2D6∗5, CYP2D6∗6, CYP2D
6∗11, CYP2D6∗12, CYP2D6∗13, CYP2D6∗14, CYP2D6∗15,
CYP2D6∗16, CYP2D6∗18, CYP2D6∗19, CYP2D6∗20, CY-
P2D6∗21, CYP2D6∗36, CYP2D6∗38, CYP2D6∗40, CYP2-
D6∗42, CYP2D6∗44, CYP2D6∗47, CYP2D6∗51, CYP2D-
6∗56, CYP2D6∗57, and CYP2D6∗62.
Ultrarapid Metabolizers (UMs): increased enzyme activ-
ity: CYP2D6∗1×N, CYP2D6∗2×N, CYP2D6∗35×2, and
CYP2D6∗53 [24, 220, 222, 223].
14.CYP2D6 Genophenotypesin
CNS Disorders
Members of most CYP families have been identiﬁed in
animal and human brains. There is extensive information
available on the regional and cellular distribution of most
CYP families in rodent brains, but very little is known
about the human brain; only CYP2D6 has been mapped
throughout the human brain. An important role ascribed
to brain CYPs is the metabolism of endogenous neurally
derived or acting compounds, such as neurotransmitters
and neurosteroids. Although CYP2D6 does not have a
primary role in the synthesis of dopamine, it may have a
modulatory eﬀect on dopamine metabolism in the brain.
CYP2D6 was found in close association with the dopamine
transporter, CYP2D enzymes have been found in dopamin-
ergic cells in the rat substantia nigra, and CYP2D6 and rat
brain-speciﬁc CYP2D18 have been implicated in dopamine
metabolism [229]. Genetic polymorphisms in CYP2D6 have
been suggested to be associated with smoking behavior,
and this modiﬁcation may occur through the involve-
ment of CYP2D6 in the dopaminergic pathway. Genetic
defects in CYP2D6 have been associated with Parkinson’s
disease, which may be linked to the role of CYP2D6 in
dopamine metabolism in the brain [229]. Not only may
CYPscontributetothemetabolismofneurotransmitters,but
neurotransmitters, their precursors, and their metabolites
mayhaveamodulatoryeﬀectonthecatalyticactivityofCYPs
in the brain. Tryptamine inhibits CYP2D6-mediated dex-
tromethorphan O-demethylation, serotonin and tryptamine
inhibit CYP1A2 phenacetin O-deethylase activity, and 5-
hydroxytryptamine and adrenaline inhibit diclofenac 4-
hydroxylation by CYP2C9 in vitro. The eﬀect of these
indoleamines and catecholamines on CYP activity suggests
that in the brain local drug metabolism by CYPs may be
modulated or regulated by endogenous neurotransmitters,
their precursors, or metabolites, and this may play a role
in the observed interindividual variability in drug response
[229].
CYP2D6 is involved in the biotransformation of many
drugs, which predominantly act in the CNS, including
opioids, many psychotropic drugs, and neurotoxins. Until
now, however, only controversial information is available26 International Journal of Alzheimer’s Disease
regarding the presence of CYP2D6 in the CNS. The regional
and cellular expression of CYP2D6 transcripts and proteins
in postmortem brain tissues of three individuals was ana-
lyzed [230]. Neuronal cells, as well as glial cells, showed
labeling for mRNA in brain regions such as the neocortex,
caudate nucleus, putamen, globus pallidus, hippocampus,
hypothalamus, thalamus, substantia nigra, and cerebellum.
In contrast, CYP2D6 protein was primarily localized in large
principal neurons such as pyramidal cells of the cortex,
pyramidal cells of the hippocampus, and Purkinje cells of
the cerebellum. In glial cells, CYP2D6 protein was absent.
TheseresultsprovideclearevidenceofCYP2D6expressionin
certainregionsoftheCNSandmayindicatetheroleCYP2D6
plays in a number of drug interactions that are of potential
clinical importance for neurological diseases [230].
The distribution and frequency of CYP2D6 genotypes
(Figure 6)a n dp h e n o t y p e s( Figure 7)w e r ei n v e s t i g a t e di n
315 Spanish controls with no family history of neuropsy-
chiatric disorders and in patients with anxiety (N = 285),
depression (N = 419), psychosis (N = 162), stroke (N =
67), Alzheimer’s disease (N = 231), Parkinson’s disease
(N = 73), attention-deﬁcit hyperactivity disorder (N = 42),
migraine (N = 217), epilepsy (N = 71), vascular dementia
(N = 198),vascularencephalopathy(withhypertension,dia-
betes, or dyslipidemia) (N = 380), multiple sclerosis (N =
21), cerebrovascular insuﬃciency (N = 138), brain tumors
(glioma, astrocytoma, glioblastoma, and meningioma) (N =
11), cranial nerve neuropathy (facial palsy, and trigeminal
neuralgia) (N = 25), mental retardation (N = 115), and
posttraumatic brain injury syndrome (N = 59) (Figures 6
and 7). In healthy subjects, EMs accounted for 55.71% of
the population, whereas IMs were 34.7%, PMs 2.28%, and
UMs 7.31% (Figure 7). Patients with depression showed sig-
niﬁcant diﬀerences in the genotypic and phenotypic proﬁles
as compared to controls (P<0.02) and also with respect to
patients with psychosis (P<0.05), Parkinson’s disease (P<
0.05), or brain tumors (P<0.05). Patients with stroke
showed diﬀerences as compared to patients with brain
tumors (P<0.05), and both patients with brain tumors
or with cranial nerve neuropathies diﬀered in their CYP2D6
phenotype with regard to controls (P<0.05). These
genophenotypic proﬁles might be important in the patho-
genesis of some CNS disorders and in the therapeutic
response to conventional psychotropic drugs as well (Figures
6 and 7).
15.CYP2D6 inAlzheimer’s Disease
In the Iberian population (Spain + Portugal), where the
mixture of ancestral cultures has occurred for centuries, the
distribution of the CYP2D6 genotypes diﬀerentiates 4 major
categoriesofCYP2D6-relatedmetabolizertypes:(i)extensive
metabolizers (EMs) (∗1/∗1,∗1/∗2,∗1/∗10), (ii) intermediate
metabolizers (IMs) (∗1/∗3, ∗1/∗4, ∗1/∗5, ∗1/∗6, ∗1/∗7,
∗10/∗10, ∗4/∗10, ∗6/∗10, ∗7/∗10), (iii) poor metabolizers
(PMs) (∗4/∗4, ∗5/∗5), and (iv) ultrarapid metabolizers
(UMs) (∗1×N/∗1, ∗1×N/∗4, Dupl). In our sample we found
51.61% EMs, 32.26% IMs, 9.03% PMs, and 7.10% UMs
[4, 6, 7, 9, 28, 112, 113, 115]. In a more recent study with
1,637 subjects and 644 patients with AD we did not ﬁnd any
signiﬁcant diﬀerence between AD cases and the general pop-
ulation (GP) [5]. A variation rate higher than 2% was found
only in the EM-∗1/∗1 genotype, which is more frequent in
theGPthaninAD.TheproportionofEMswas59.51%inGP
and57.76%inAD;IMswere29%inGPand31%inAD;PMs
were 4.46% in GP and 5.27% in AD; UMs were 6.23% in GP
and 5.9% in AD [5]. No major diﬀerences between females
and males were found in the GP group; however, in AD, EMs
are more frequent in females than in males, and PMs are
morefrequentinmalesthaninfemales,indicatingthatmales
might be at higher risk for developing ADRs [5].
16.Associationof CYP2D6 Variantswith
Alzheimer’s Disease-RelatedGenes
We have also investigated the association of CYP2D6
genotypes with AD-related genes, such as APP, MAPT,
APOE, PSEN1, PSEN2, A2M, ACE, AGT, FOS,a n dPRNP
variants [4–7, 112, 113]. Homozygous APOE-2/2 (12.56%)
and APOE-4/4 (12.50%) accumulate in UMs, and APOE-
4/4 cases were also more frequent in PMs (6.66%) than
in EMs (3.95%) or IMs (0%). PSEN1-1/1 genotypes were
more frequent in EMs (45%), whereas PSEN-1/2 genotypes
were overrepresented in IMs (63.16%) and UMs (60%).
The presence of the PSEN1-2/2 genotype was especially
high in PMs (38.46%) and UMs (20%). A mutation in the
PSEN2 gene exon 5 (PS2E5+) was markedly present in UMs
(66.67%). About 100% of UMs were A2M-V100I-A/A, and
the A2M-V100I-G/G genotype was absent in PMs and UMs.
The A2M-I/I genotype was absent in UMs, and 100% of
UMs were A2M-I/D and ACE-D/D. Homozygous mutations
in the FOS gene (B/B) were also only present in UMs. AGT-
T235T cases were absent in PMs, and the AGT-M174M
genotype appeared in 100% of PMs. Likewise, the PRNP-
M129Mvariantwaspresentin100%ofPMsandUMs.These
association studies clearly show that in PMs and UMs there
is an accumulation of AD-related polymorphic variants of
risk which might be responsible for the defective therapeutic





It appears that diﬀerent CYP2D6 variants, expressing EMs,
IMs, PMs, and UMs, inﬂuence to some extent several
biochemical parameters, liver function, and vascular hemo-
dynamic parameters, which might aﬀect drug eﬃcacy and
safety. Blood glucose levels are found to be elevated in EMs
(∗1/∗1 versus ∗4/∗10) and in some IMs (∗4/∗10 versus
∗1×N/∗4), whereas other IMs (∗1/∗5 versus ∗4/∗4)t e n dt o
show lower levels of glucose compared with PMs (∗4/∗4)
or UMs (∗1×N/∗4). The highest levels of total cholesterol
are detected in the EMs with the CYP2D6∗1/∗10 genotype
(versus ∗1/∗1, ∗1/∗4, and ∗1×N/∗1) .T h es a m ep a t t e r nh a sInternational Journal of Alzheimer’s Disease 27
Figure 6: Distribution and frequency of CYP2D6 variants in patients with CNS disorders. C: controls; ANX: anxiety; DEP: depression; PSY:
psychotic disorders; STR: stroke; AD: Alzheimer’s disease; PAR: Parkinson’s disease; ADHD: attention-deﬁcit hyperactivity disorder; MIG:
migraine; EPI: epilepsy; VD: vascular dementia; VE: vascular encephalopathy; MS: multiple sclerosis; CVI: cerebrovascular insuﬃciency; BT:
brain tumors; CNN: cranial nerve neuropathies; MR: mental retardation; PTBS: posttraumatic brain injury syndrome. Source: R. Cacabelos.
CIBE Database. EuroEspes Biomedical Research Center, Institute for CNS Disorders, Coru˜ na, Spain.
been observed with regard to LDL-cholesterol levels, which
are signiﬁcantly higher in the EM-∗1/∗10. In general, both
total cholesterol levels and LDL-cholesterol levels are higher
in EMs (with a signiﬁcant diﬀerence between ∗1/∗1 and
∗1/∗10), intermediate levels are seen in IMs, and much
lower levels in PMs and UMs; and the opposite occurs
with HDL-cholesterol levels, which on average appear much
lower in EMs than in IMs, PMs, and UMs, with the highest
levels detected in ∗1/∗3 and ∗1×N/∗4. The levels of
triglycerides are highly variable among diﬀerent CYP2D6
polymorphisms, with the highest levels present in IMs
(∗4/∗10 versus ∗4/∗5 and ∗1×N/∗1)[ 4, 6, 115]. These data
clearly indicate that lipid metabolism can be inﬂuenced by
CYP2D6 variants or that speciﬁc phenotypes determined
by multiple lipid-related genomic clusters are necessary to
confer the character of EMs and IMs. Another possibility
might be thatsome lipid metabolism genotypes interactwith
CYP2D6-related enzyme products, leading to the deﬁnition
of the pheno-genotype of PMs and UMs. No signiﬁcant
changes in blood pressure values have been found among
CYP2D6 genotypes; however, important diﬀerences became
apparent in brain cerebrovascular hemodynamics. The best
cerebrovascular hemodynamic pattern is observed in EMs
and PMs, with higher brain blood ﬂow velocities and lower
resistance and pulsatility indices, but diﬀerential phenotypic
proﬁles are detectable among CYP2D6 genotypes. Systolic28 International Journal of Alzheimer’s Disease
Figure 7: Distribution and frequency of CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), poor metabolizers (PMs),
and ultrarapid metabolizers (UMs) in patients with diﬀe r e n tC N Sd i s o r d e r s .C :c o n t r o l s ;A N X :a n x i e t y ;D E P :d e p r e s s i o n ;P S Y :p s y c h o t i c
disorders; STR: stroke; AD: Alzheimer’s disease; PAR: Parkinson’s disease; ADHD: attention-deﬁcit hyperactivity disorder; MIG: migraine;
EPI: epilepsy; VD: vascular dementia; VE: vascular encephalopathy; MS: multiple sclerosis; CVI: cerebrovascular insuﬃciency; BT: brain
tumors; CNN: cranial nerve neuropathies; MR: mental retardation; PTBS: posttraumatic brain injury syndrome. Source: R. Cacabelos. CIBE
Database. EuroEspes Biomedical Research Center, Institute for CNS Disorders, Coru˜ na, Spain.
blood ﬂow velocities (Sv) in the left middle cerebral arteries
(LMCA) of AD patients are signiﬁcantly lower in ∗1/∗10
EMs, with high total cholesterol and LDL-cholesterol levels,
t h a ni nI M s( ∗4/∗10); diastolic velocities (Dv) also tend to
be much lower in ∗1/∗10 and especially in PMs (∗4/∗4)a n d
UMs (∗1×N/∗4), whereas the best Dv is measured in ∗1/∗5
IMs. More striking are the results of both the pulsatility
index (PI = (Sv − Dv)/Mv) and resistance index (RI =
(Sv−Dv)/S v ) ,w h i c ha r ew o r s ei nI M sa n dP M st h a ni nE M s
and UMs. These data taken together seem to indicate that
CYP2D6-related AD PMs exhibit a poorer cerebrovascular
function which might aﬀect drug penetration into the brain,
with the consequent therapeutic implications [4, 6, 7, 112–
115].
18. Inﬂuence of CYP2D6 Genotypeson
LiverTransaminaseActivity
UMsandPMstendtoshowthehighestGOTactivityandIMs
the lowest. Signiﬁcant diﬀerences appear among diﬀerent
IM-related genotypes. The ∗10/∗10 genotype exhibited the
lowest GOT activity with marked diﬀerences as compared
to UMs. GPT activity was signiﬁcantly higher in PMs
(∗4/∗4) than in EMs (∗1/∗10)o rI M s( ∗1/∗4 and∗1/∗5).
The lowest GPT activity was found in EMs and IMs. Strik-
ing diﬀerences have been found in GGT activity between
PMs (∗4/∗4), which showed the highest levels, and EMs
(∗1/∗1 and ∗1/∗10), IMs (∗1/∗5), or UMs (∗1×N/∗1)[ 6].
Interesting enough, the ∗10/∗10 genotype, with the lowest
values of GOT and GPT, exhibited the second highest levels
of GGT after ∗4/∗4, probably indicating that CYP2D6-
related enzymes diﬀerentially regulate drug metabolism and
transaminase activity in the liver. These results are also clear
in demonstrating the direct eﬀect of CYP2D6 variants on
transaminase activity [4, 6, 7].
19.CYP2D6-RelatedTherapeuticResponseto
a MultifactorialTreatment in Dementia
With a multifactorial therapeutic intervention in patients
with dementia who received (a) an endogenous nucleotide
and choline donor, CDP-choline (500mg/day), (b) aInternational Journal of Alzheimer’s Disease 29
nootropic substance, piracetam (1600mg/day), (c) a vasoac-
tive compound, 1,6 dimethyl 8β-(5-bromonicotinoyl-oxym-
ethyl)-10α-methoxyergoline (nicergoline) (5mg/day), and
(d) a cholinesterase inhibitor, donepezil (5mg/day), for one
year, EMs improved their cognitive function (MMSE score)
from 21.58 ± 9.02 at baseline to 23.78 ± 5.81 after 1-year
treatment. IMs also improved from 21.40 ± 6.28 to 22.50 ±
5.07 (r = +0.96), whereas PMs and UMs deteriorated from
20.74 ± 6.72 to 18.07 ± 5.52 (r =− 0.97) and from 22.65 ±
6.76 to 21.28 ± 7.75 (r =− 0.92), respectively. According
to these results, PMs and UMs were the worst responders,
showing a progressive cognitive decline with no therapeutic
eﬀect, and EMs and IMs were the best responders, with a
clear improvement in cognition after one year of treatment.
Among EMs, AD patients harboring the ∗1/∗10 genotype
responded better than patients with the ∗1/∗1 genotype.
The best responders among IMs were the ∗1/∗3, ∗1/∗6, and
∗1/∗5 genotypes, whereas the ∗1/∗4, ∗10/∗10, and ∗4/∗10
genotypes were poor responders. Among PMs and UMs, the
poorest responders were carriers of the ∗4/∗4 and ∗1×N/∗1
genotypes, respectively [4–7, 9, 28, 112, 113]. In a recent
study, Pilotto et al. [231] have conﬁrmed the inﬂuence of
CYP2D6 variants (rs1080985) on the eﬃcacy of donepezil in
AD.
Fromallthesedatainpatientswithdementiawecancon-
clude the following. (i) The most frequent CYP2D6 variants
in the Southern European population (Iberian peninsula)
are the ∗1/∗1 (57.84%), ∗1/∗4 (22.78%), ∗1×N/∗1 (6.10%),
∗4/∗4 (2.56%), and ∗1/∗3 (2.01%) genotypes, accounting
for more than 80% of the population; (ii) the frequency
of EMs, IMs, PMs, and UMs is about 59.51%, 29.78%,
4.46%, and 6.23%, respectively, in the general population,
and 57.76, 31.05%, 5.27%, and 5.90%, respectively, in AD
cases; (iii) EMs are more prevalent in GP (59.51%) than in
AD (57.76%); IMs are more frequent in AD (31.05%) than
in GP (29.78%); the frequency of PMs is slightly higher in
AD (5.27%) than in GP (4.46%); UMs are more frequent in
GP (6.23%) than in AD (5.90%); (iv) there are diﬀerences
between females and males in the distribution and frequency
of CYP2D6 genotypes, which might be of relevance in thera-
peutic terms and risk of ADRs; (v) there is an accumulation
of AD-related genes of risk in PMs and UMs; (vi) PMs and
UMs tend to show higher transaminase activities than EMs
and IMs; (vii) EMs and IMs are the best responders, and
PMs and UMs are the worst responders to a combination
therapywithcholinesteraseinhibitors,neuroprotectants,and
vasoactivesubstances;(viii)thepharmacogeneticresponsein
AD appears to be dependent upon the networking activity of
genes involved in drug metabolism and genes involved in AD
pathogenesis [4–7, 9, 28, 105, 112, 113].
20.CYP Clustering
Since over half of the available drugs are metabolized via
diﬀerent CYP enzymes and other metabolic pathways, it is
convenient to understand the networking activity of CYP
genes and the genomic proﬁles of these genes in particular
groups of risk. In the case of dementia, 73.71% of AD
patients are CYP2C19-EMs, 25.12% IMs, and 1.16% PMs.
The distribution and frequency of CYP2C9 genotypes is as
follows: ∗1/∗1-EM 60.87%, ∗1/∗2-IM 23.98%, ∗1/∗3-IM
10.17%, ∗2/∗2-PM 2.54%, ∗2/∗3-PM 2.16%, and ∗3/∗3-
PM 0.25%, globally representing 60.87% CYP2C9-EMs,
34.16% IMs, and 4.97% PMs [5]. This is especially impor-
tant because the CYP2C9-Ile359Leu (CYP2C9∗3 allele) and
CYP2C9-Arg144Cys (CYP2C9∗2 allele) variants are associ-
ated with warfarin sensitivity. Clustering together CYP2C9
and VKORC1 variants, we can estimate that approximately
30% of the elderly population is sensitive to warfarin
anticoagulants.
Concerning CYP3A4/5 polymorphisms, 82.75% of AD
c a s e sa r eE M s( CYP3A5∗3/∗3), 15.88% are IMs (CY-
P3A5∗1/∗3), and 1.37% are UMs (CYP3A5∗1/∗1)[ 5].
The construction of a genetic map integrating the most
prevalent CYP2D6 + CYP2C19 + CYP2C9 polymorphic
variants in a trigenic cluster yields 82 diﬀerent haplotype-
like proﬁles. The most frequent trigenic genotypes in the
AD population are ∗1∗1-∗1∗1-∗1∗1 (25.70%), ∗1∗1-∗1∗2-
∗1∗2 (10.66%), ∗1∗1-∗1∗1-∗1∗1 (10.45%), ∗1∗4-∗1∗1-
∗1∗1 (8.09%), ∗1∗4-∗1∗2-∗1∗1 (4.91%), ∗1∗4-∗1∗1-∗1∗2
(4.65%), and ∗1∗1-∗1∗3-∗1∗3 (4.33%). These 82 trigenic
genotypes represent 36 diﬀerent pharmacogenetic pheno-
types.Accordingtothesetrigenicclusters,only26.51%ofthe
patients show a pure 3EM phenotype, 15.29% are 2EM1IM,
2.04%arepure3IM,0%arepure3PM,and0%are1UM2PM
(the worst possible phenotype) [5].
Taking into consideration the data available, it might
be inferred that at least 10–15% of the AD population
may exhibit an abnormal metabolism of cholinesterase
inhibitors and/or other drugs, which undergo oxidation
via CYP2D6-related enzymes. Approximately 50% of this
population cluster would show an ultrarapid metabolism,
requiring higher doses of cholinesterase inhibitors in order
to reach a therapeutic threshold, whereas the other 50%
of the cluster would exhibit a poor metabolism, displaying
potential adverse events at low doses. If we take into account
that approximately 60–70% of therapeutic outcomes depend
upon pharmacogenomic criteria (e.g., pathogenic mecha-
nismsassociatedwithAD-relatedgenes),itcanbepostulated
that pharmacogenetic and pharmacogenomic factors are
responsiblefor75–85%ofthetherapeuticresponse(eﬃcacy)




and pharmacogenomics would be the followung: (i) AD is
a complex disorder in which many diﬀerent gene clusters
may be involved; (ii) most genes screened to date belong to
diﬀerent proteomic and metabolomic pathways potentially
aﬀecting AD pathogenesis; (iii) the APOE g e n es e e m st ob ea
major risk factor for both degenerative and vascular demen-
tia; (iv) the therapeutic response to conventional drugs
in patients with AD is genotype-speciﬁc, with CYP2D6-
PMs, CYP2D6-UMs, and APOE-4/4 carriers acting as the30 International Journal of Alzheimer’s Disease
worst responders; (v) APOE and CYP2D6 may cooperate,
as pleiotropic genes, in the metabolism of drugs and
hepatic function; (vi) the introduction of pharmacogenetic
procedures into AD pharmacological treatment may help to
optimize therapeutics.
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